1
|
Song M, Qu Y, Jia H, Zhang Y, Liu S, Laster KV, Choi BY, Tian J, Gu T, Chen H, Liu K, Lee MH, Dong Z. Targeting TAOK1 with resveratrol inhibits esophageal squamous cell carcinoma growth in vitro and in vivo. Mol Carcinog 2024; 63:991-1008. [PMID: 38376345 DOI: 10.1002/mc.23703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2023] [Revised: 01/23/2024] [Accepted: 02/05/2024] [Indexed: 02/21/2024]
Abstract
The worldwide incidence and mortality rates of esophageal squamous cell carcinoma (ESCC) have increased over the last decade. Moreover, molecular targets that may benefit the therapeutics of patients with ESCC have not been fully characterized. Our study discovered that thousand and one amino-acid protein kinase 1 (TAOK1) is highly expressed in ESCC tumor tissues and cell lines. Knock-down of TAOK1 suppresses ESCC cell proliferation in vitro and patient-derived xenograft or cell-derived xenograft tumors growth in vivo. Moreover, TAOK1 overexpression promotes ESCC growth in vitro and in vivo. Additionally, we identified that the natural small molecular compound resveratrol binds to TAOK1 directly and diminishes the kinase activity of TAOK1. Targeting TAOK1 directly with resveratrol significantly inhibits cell proliferation, induces cell cycle arrest and apoptosis, and suppresses tumor growth in ESCC. Furthermore, the silencing of TAOK1 or the application of resveratrol attenuated the activation of TAOK1 downstream signaling effectors. Interestingly, combining resveratrol with paclitaxel, cisplatin, or 5-fluorouracil synergistically enhanced their therapeutic effects against ESCC. In conclusion, this work illustrates the underlying oncogenic function of TAOK1 and provides a theoretical basis for the application of targeting TAOK1 therapy to the clinical treatment of ESCC.
Collapse
Affiliation(s)
- Mengqiu Song
- Department of Pathophysiology, School of Basic Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou, Henan, China
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China
- State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University, Zhengzhou, Henan, China
| | - Yingzi Qu
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China
- The Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, Henan, China
| | - Huajie Jia
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China
- The Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, Henan, China
| | - Yunqing Zhang
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China
- The Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, Henan, China
| | - Shihui Liu
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China
- The Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, Henan, China
| | | | - Bu Young Choi
- Department of Pharmaceutical Science & Engineering, Seowon University, Cheongju, South Korea
| | - Jie Tian
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China
- The Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, Henan, China
| | - Tingxuan Gu
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China
- The Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, Henan, China
| | - Hanyong Chen
- The Hormel Institute, University of Minnesota, Austin, Minnesota, USA
| | - Kangdong Liu
- Department of Pathophysiology, School of Basic Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou, Henan, China
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China
- State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University, Zhengzhou, Henan, China
- The Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, Henan, China
- Provincial Cooperative Innovation Center for Cancer Chemoprevention, Zhengzhou University, Zhengzhou, China
- Cancer Chemoprevention International Collaboration Laboratory, Zhengzhou, China
| | - Mee-Hyun Lee
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China
- College of Korean Medicine, Dongshin University, Naju, Republic of Korea
| | - Zigang Dong
- Department of Pathophysiology, School of Basic Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou, Henan, China
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China
- State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University, Zhengzhou, Henan, China
- The Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, Henan, China
- Cancer Chemoprevention International Collaboration Laboratory, Zhengzhou, China
| |
Collapse
|
2
|
Lin QH, Yan SD, Zhang X, Chen SW, Li XY, Zhang Y, Zhang ST, Song M. [Prediction of pathological remission of head and neck squamous cell carcinoma patients after neoadjuvant immunochemotherapy and construction of clinical model based on clinical features and inflammatory markers]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2024; 59:357-365. [PMID: 38599643 DOI: 10.3760/cma.j.cn115330-20231226-00331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/12/2024]
Abstract
Objective: To analyze the potential clinical biological factors influencing the major pathological response (MPR) to neoadjuvant immunochemotherapy in patients with resectable head and neck squamous cell carcinoma (HNSCC). Methods: This retrospective study enrolled patients with resectable HNSCC who underwent neoadjuvant immunochemotherapy at Sun Yat-sen University Cancer Center from June 1, 2019 to December 31, 2021. Binary logistic regression was used to analyze the correlation between clinical characteristics, inflammatory markers and MPR, and a nomogram model was constructed. The calibration curve and decision curve analysis were used to verify the predictive ability and accuracy of the nomogram model. Results: A total of 173 patients were included in the study, with 141 males and 32 females, aged from 22 to 83 years. After pathological assessment, the patients were divided into two groups: MPR group (108 cases) and non MPR group (65 cases). Logistics regression analysis indicated that the patients with HPV+oropharyngeal cancer, partial response or complete response by imaging assessment, low pre-treatment platelet/lymphocyte ratio, low pre-treatment C reactive protein/albumin ratio and lower pre-and post-treatment C reactive protein/albumin ratio difference were more likely to have MPR (all P<0.05). Nomogram model was constructed based on the above factors, with a C-index of 0.826 (95%CI: 0.760-0.892), and the calibration curve and decision curve analysis confirmed the prediction accuracy of the model. Conclusion: This study shows that many factors are related to MPR of patients with resectable HNSCC receiving neoadjuvant immunochemotherapy and the constructed nomogram model helps to develop personalized treatment strategies for the patients.
Collapse
Affiliation(s)
- Q H Lin
- State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - S D Yan
- State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - X Zhang
- State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - S W Chen
- State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - X Y Li
- State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - Y Zhang
- State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - S T Zhang
- State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - M Song
- State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| |
Collapse
|
3
|
Laskar RS, Qu C, Huyghe JR, Harrison T, Hayes RB, Cao Y, Campbell PT, Steinfelder R, Talukdar FR, Brenner H, Ogino S, Brendt S, Bishop DT, Buchanan DD, Chan AT, Cotterchio M, Gruber SB, Gsur A, van Guelpen B, Jenkins MA, Keku TO, Lynch BM, Le Marchand L, Martin RM, McCarthy K, Moreno V, Pearlman R, Song M, Tsilidis KK, Vodička P, Woods MO, Wu K, Hsu L, Gunter MJ, Peters U, Murphy N. Genome-wide association studies and Mendelian randomization analyses provide insights into the causes of early-onset colorectal cancer. Ann Oncol 2024:S0923-7534(24)00058-9. [PMID: 38408508 DOI: 10.1016/j.annonc.2024.02.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 01/30/2024] [Accepted: 02/20/2024] [Indexed: 02/28/2024] Open
Abstract
BACKGROUND The incidence of early-onset colorectal cancer (EOCRC; diagnosed <50 years of age) is rising globally; however, the causes underlying this trend are largely unknown. CRC has strong genetic and environmental determinants, yet common genetic variants and causal modifiable risk factors underlying EOCRC are unknown. We conducted the first EOCRC-specific genome-wide association study (GWAS) and Mendelian randomization (MR) analyses to explore germline genetic and causal modifiable risk factors associated with EOCRC. PATIENTS AND METHODS We conducted a GWAS meta-analysis of 6176 EOCRC cases and 65 829 controls from the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), the Colorectal Transdisciplinary Study (CORECT), the Colon Cancer Family Registry (CCFR), and the UK Biobank. We then used the EOCRC GWAS to investigate 28 modifiable risk factors using two-sample MR. RESULTS We found two novel risk loci for EOCRC at 1p34.1 and 4p15.33, which were not previously associated with CRC risk. We identified a deleterious coding variant (rs36053993, G396D) at polyposis-associated DNA repair gene MUTYH (odds ratio 1.80, 95% confidence interval 1.47-2.22) but show that most of the common genetic susceptibility was from noncoding signals enriched in epigenetic markers present in gastrointestinal tract cells. We identified new EOCRC-susceptibility genes, and in addition to pathways such as transforming growth factor (TGF) β, suppressor of Mothers Against Decapentaplegic (SMAD), bone morphogenetic protein (BMP) and phosphatidylinositol kinase (PI3K) signaling, our study highlights a role for insulin signaling and immune/infection-related pathways in EOCRC. In our MR analyses, we found novel evidence of probable causal associations for higher levels of body size and metabolic factors-such as body fat percentage, waist circumference, waist-to-hip ratio, basal metabolic rate, and fasting insulin-higher alcohol drinking, and lower education attainment with increased EOCRC risk. CONCLUSIONS Our novel findings indicate inherited susceptibility to EOCRC and suggest modifiable lifestyle and metabolic targets that could also be used to risk-stratify individuals for personalized screening strategies or other interventions.
Collapse
Affiliation(s)
- R S Laskar
- Nutrition and Metabolism Branch, International Agency for Research on Cancer, World Health Organization, Lyon, France; Early Cancer Institute, Department of Oncology, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
| | - C Qu
- Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle
| | - J R Huyghe
- Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle
| | - T Harrison
- Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle
| | - R B Hayes
- Division of Epidemiology, Department of Population Health, New York University School of Medicine, New York
| | - Y Cao
- Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis; Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, St Louis; Alvin J. Siteman Cancer Center, St Louis
| | - P T Campbell
- Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, USA
| | - R Steinfelder
- Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle
| | - F R Talukdar
- Epigenomics and Mechanisms Branch, International Agency for Research on Cancer, World Health Organization, Lyon, France; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
| | - H Brenner
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - S Ogino
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Program in Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston
| | - S Brendt
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, USA
| | - D T Bishop
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
| | - D D Buchanan
- Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Melbourne; Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, Australia
| | - A T Chan
- Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, USA
| | - M Cotterchio
- Ontario Health (Cancer Care Ontario), Toronto; Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
| | - S B Gruber
- Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, USA
| | - A Gsur
- Center for Cancer Research, Medical University of Vienna, Vienna, Austria
| | - B van Guelpen
- Department of Radiation Sciences, Oncology Unit, Umeå University, Umeå; Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden
| | - M A Jenkins
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia
| | - T O Keku
- Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, USA
| | - B M Lynch
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne; Physical Activity Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia
| | | | - R M Martin
- Medical Research Council (MRC) Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol; National Institute for Health Research (NIHR) Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol, Bristol
| | - K McCarthy
- Department of Colorectal Surgery, North Bristol NHS Trust, Bristol, UK
| | - V Moreno
- Cancer Prevention and Control Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona; CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | - R Pearlman
- Division of Human Genetics, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus
| | - M Song
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, USA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, USA
| | - K K Tsilidis
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK; Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece
| | - P Vodička
- Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague; Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague; Faculty of Medicine and Biomedical Center in Pilsen, Charles University, Pilsen, Czech Republic
| | - M O Woods
- Memorial University of Newfoundland, Discipline of Genetics, St. John's, Canada
| | - K Wu
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, USA
| | - L Hsu
- Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle
| | - M J Gunter
- Nutrition and Metabolism Branch, International Agency for Research on Cancer, World Health Organization, Lyon, France; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
| | - U Peters
- Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle; Department of Epidemiology, University of Washington, Seattle, USA
| | - N Murphy
- Nutrition and Metabolism Branch, International Agency for Research on Cancer, World Health Organization, Lyon, France.
| |
Collapse
|
4
|
Song M, Wang W, Ji C, Li S, Liu W, Hu X, Feng A, Ruan S, Du S, Wang H, Dai K, Guo L, Qian Q, Si H, Hu X. Simultaneous production of high-frequency synthetic apomixis with high fertility and improved agronomic traits in hybrid rice. Mol Plant 2024; 17:4-7. [PMID: 37990497 DOI: 10.1016/j.molp.2023.11.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/30/2023] [Revised: 10/18/2023] [Accepted: 11/18/2023] [Indexed: 11/23/2023]
Abstract
The current apomixis system used in fixing heterozygosity suffers from the problems of low fertility and limited apomixis induction rate. This study implies that egg-cell-specific expression of dandelion's PAR combined with MiMe in hybrid rice can efficiently trigger highly fertile synthetic apomixis for effective clonal propagation of hybrids.
Collapse
Affiliation(s)
- Mengqiu Song
- College of Agronomy, Anhui Agricultural University, Hefei, Anhui 230036, China
| | - Wumei Wang
- Rice Research Institute, Anhui Academy of Agricultural Sciences, Hefei, Anhui 230031, China
| | - Chun Ji
- Jiangxi Modern Seed Industry, Co., Nanchang, Jiangxi 330026, China
| | - Shengnan Li
- College of Agronomy, Anhui Agricultural University, Hefei, Anhui 230036, China
| | - Wei Liu
- College of Agronomy, Anhui Agricultural University, Hefei, Anhui 230036, China
| | - Xiaoyu Hu
- College of Agronomy, Anhui Agricultural University, Hefei, Anhui 230036, China
| | - Anhui Feng
- College of Agronomy, Anhui Agricultural University, Hefei, Anhui 230036, China
| | - Shuang Ruan
- College of Agronomy, Anhui Agricultural University, Hefei, Anhui 230036, China
| | - Shiyun Du
- Rice Research Institute, Anhui Academy of Agricultural Sciences, Hefei, Anhui 230031, China
| | - Huan Wang
- Jiangxi Modern Seed Industry, Co., Nanchang, Jiangxi 330026, China
| | - Kui Dai
- Jiangxi Modern Seed Industry, Co., Nanchang, Jiangxi 330026, China
| | - Longbiao Guo
- State Key Laboratory of Rice Biology, China National Rice Research Institute, Hangzhou, Zhejiang 310006, China
| | - Qian Qian
- State Key Laboratory of Rice Biology, China National Rice Research Institute, Hangzhou, Zhejiang 310006, China.
| | - Hongqi Si
- College of Agronomy, Anhui Agricultural University, Hefei, Anhui 230036, China.
| | - Xingming Hu
- College of Agronomy, Anhui Agricultural University, Hefei, Anhui 230036, China.
| |
Collapse
|
5
|
Luo H, Sun Y, Wang L, Liu H, Zhao R, Song M, Ge H. Targeting endoplasmic reticulum associated degradation pathway combined with radiotherapy enhances the immunogenicity of esophageal cancer cells. Cancer Biol Ther 2023; 24:2166763. [PMID: 36907982 PMCID: PMC10026871 DOI: 10.1080/15384047.2023.2166763] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2022] [Revised: 12/15/2022] [Accepted: 01/03/2023] [Indexed: 03/14/2023] Open
Abstract
Immunogenic cell death (ICD) is essential for the activation of immune system against cancer. We aimed to investigate the efficacy of endoplasmic reticulum (ER)-associated protein degradation (ERAD) inhibitors (EerI and NMS-873) in enhancing radiation-induced ICD in esophageal cancer (EC). EC cells were administered with ERAD inhibitors, radiation therapy (RT), and the combination treatment. ICD hallmarks including calreticulin (CALR), adenosine triphosphate (ATP), and high mobility group protein B1 (HMGB1) were detected. The efficacy of ERAD inhibitors combined with RT in stimulating ICD was analyzed. Additionally, the role of ICD hallmarks in immune cell infiltration and patient survival was investigated. Inhibiting ERAD pathways was able to stimulate ICD component emission from dying EC cells in a dose-dependent pattern. Radiation-induced ICD was significantly increased after high doses RT (≥10 Gy). ERAD inhibitor combined with moderate dose RT (≥6 Gy) was capable of stimulating increased ICD in EC cells. Dual therapy could elicit the antitumor immune response by enhancing dendritic cells maturation and phagocytosis. Further investigation revealed a significant correlation between CALR and tumor-infiltrating immune cells. Low expression of ATP and HMGB1 and high expression of CALR were associated with favorable survival in patients with EC. The immunogenicityof EC can be enhanced by ERAD inhibitors combined with moderate doses of RT. ICD hallmark genes, especially CALR, are correlated to immune cell infiltration and clinical outcomes in EC. The present results demonstrated an important method to improve the immunogenicity of EC cells for enhanced antitumor immune response.
Collapse
Affiliation(s)
- Hui Luo
- Laboratory of Radiation Oncology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
| | - Yanan Sun
- Laboratory of Radiation Oncology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
| | - Liuxiang Wang
- Academic of Medical Science, Zhengzhou University, Zhengzhou, China
| | - Hui Liu
- Department of Basic Medicine, China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Ran Zhao
- Department of Basic Medicine, China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Mengqiu Song
- Department of Basic Medicine, China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Hong Ge
- Laboratory of Radiation Oncology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
| |
Collapse
|
6
|
Song M, Fumagalli P, Schmid M. Scanning near-field optical microscopy measurements and simulations of regularly arranged silver nanoparticles. Nanotechnology 2023; 35:065702. [PMID: 37931313 DOI: 10.1088/1361-6528/ad0a0e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Accepted: 11/06/2023] [Indexed: 11/08/2023]
Abstract
Silver nanoparticles on a glass substrate are experimentally investigated by aperture scanning near-field optical microscopy (a-SNOM). To understand the experimental results, finite-element-method simulations are performed building a theoretical model of the a-SNOM geometry. We systematically vary parameters like aperture size, aluminum-coating thickness, tip cone angle, and tip-surface distance and discuss their influence on the near-field enhancement. All these investigations are performed comparatively for constant-height and constant-gap scanning modes. In the end, we establish a reliable and stable optical model for simulating a-SNOM measurements, which is capable of reproducing trends observed in experimental data.
Collapse
Affiliation(s)
- M Song
- Institut für Experimentalphysik, Freie Universität Berlin, D-14195 Berlin, Germany
- Nanooptische Konzepte für die PV, Helmholtz-Zentrum Berlin für Materialien und Energie GmbH, D-14109 Berlin, Germany
| | - P Fumagalli
- Institut für Experimentalphysik, Freie Universität Berlin, D-14195 Berlin, Germany
| | - M Schmid
- Institut für Experimentalphysik, Freie Universität Berlin, D-14195 Berlin, Germany
- Nanooptische Konzepte für die PV, Helmholtz-Zentrum Berlin für Materialien und Energie GmbH, D-14109 Berlin, Germany
- Faculty of Physics and CENIDE, University of Duisburg-Essen, Forsthausweg 2, D-47057 Duisburg, Germany
| |
Collapse
|
7
|
Li S, Zhu X, Song M, Xiang Y, Zhang Y, Wang HZ, Geng J, Liu Z, Teng H, Cai Y, Li Y, Wang W. Outcomes and Failure Patterns after Chemoradiotherapy for Locally Advanced Rectal Cancer with Positive Lateral Pelvic Lymph Nodes: A Propensity Score-Matched Analysis. Int J Radiat Oncol Biol Phys 2023; 117:e314. [PMID: 37785131 DOI: 10.1016/j.ijrobp.2023.06.2345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Locally advanced rectal cancer (LARC) combined with positive lateral pelvic lymph nodes (LPLN) tends to present worse prognosis. However, for those patients it remains unclear whether other combination high-risk factors affect the prognosis. This study aimed to use propensity score matching (PSM) to examine long-term outcomes and failure patterns in patients with positive vs. negative LPLN. MATERIALS/METHODS Patients with LARC were retrospectively divided into LPLN-positive and LPLN-negative groups. LPLN-positivity was defined as lymph node short diameter greater than or equal to 7 mm with specific morphological features. Clinical characteristics were compared between the groups using the chi-square test. PSM was applied to balance these differences. Progression-free survival (PFS) and overall survival (OS), and local-regional recurrence (LRR) and distant metastasis (DM) rates were compared between the groups using the Kaplan-Meier method and log-rank tests. RESULTS Prior to PSM, a total of 651 LARC patients were included. The LPLN-positive group had higher rates of lower location (53.1% vs. 43.0%, P = 0.025), mesorectal fascia (MRF)-positive (53.9% vs. 35.4%, P<0.001) and extramural venous invasion (EMVI)-positive (51.2% vs. 27.2%, P<0.001) disease than the LPLN-negative group. After PSM, there were 114 patients for each group along with the balanced clinical factors, and both groups had comparable surgery, pathologic complete response (pCR), and ypN stage rates. The median follow-up time was 45.9 months, 3-year OS (88.3% vs. 92.1%, P = 0.276) and LRR (5.7% vs. 2.8%, P = 0.172) rates were comparable between LPLN-positive and LPLN-negative groups. Meanwhile, despite no statistical difference, 3-year PFS (78.8% vs. 85.9%, P = 0.065) and DM (20.4% vs. 13.3%, P = 0.061) rates slightly differed between the groups. Among 10 patients with LRR, seven (70.0%) had lateral pelvic recurrence, among them, five patients were LPLN-positive, and four (80.0%) of these patients did not receive simultaneous integrated boost intensity-modulated radiotherapy (SIB- IMRT).45 patients were diagnosed with DM, 11 (40.7%) LPLN-positive and 3 (17.6%) LPLN-negative patients were diagnosed with oligometastases (P = 0.109). CONCLUSION Our study shows there is a tendency of worse PFS and DM in LPLN-positive than LPLN-negative patients, for LPLN-positive patients, oligometastases account for a large proportion of all distant metastases.
Collapse
Affiliation(s)
- S Li
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - X Zhu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - M Song
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - Y Xiang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - Y Zhang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - H Z Wang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - J Geng
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - Z Liu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - H Teng
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - Y Cai
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - Y Li
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - W Wang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| |
Collapse
|
8
|
Wang HZ, Zheng X, Sun J, Zhu X, Dong D, Du Y, Feng Z, Gong J, Wu H, Geng J, Li S, Song M, Zhang Y, Liu Z, Cai Y, Li Y, Wang W. 4D-MRI Guided Stereotactic Body Radiation Therapy for Unresectable Colorectal Liver Metastases. Int J Radiat Oncol Biol Phys 2023; 117:e359. [PMID: 37785235 DOI: 10.1016/j.ijrobp.2023.06.2445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) This study evaluated the feasibilities and outcomes following four-dimensional magnetic resonance imaging (4D-MRI) guided stereotactic body radiation therapy (SBRT) for unresectable colorectal liver metastases (CRLM). MATERIALS/METHODS From March 2018 to January 2022, we identified 76 unresectable CRLM patients with 123 lesions who received 4D-MRI guided SBRT in our institution. 4D-MRI simulation with or without abdominal compression was conducted for all patients. The prescription dose was 50-65 Gy in 5-12 fractions. The image quality of computed tomography (CT) and MRI were compared using the Clarity Score. Clinical outcomes and toxicity profiles were evaluated. RESULTS The 4D-MRI significantly improved the image quality compared with CT images (mean Clarity Score: 1.67 vs 2.88, P < 0.001). The abdominal compression significantly reduced motions in cranial-caudal direction (P = 0.03) with 2 phase T2 weighted images assessing tumor motion. The median follow-up time was 12.5 months. For 98 lesions assessed for best response, the complete response, partial response and stable disease rate were 57.1 %, 30.6 % and 12.2 %, respectively. The local control (LC) rate at 2 year was 97.3%. 46.1% of patients experienced grade 1-2 toxicities and only 2.6% patients experienced grade 3 hematologic toxicities. CONCLUSION The 4D-MRI technique allowed precise target delineation and motion tracking in unresectable CRLM patients. High LC rate and mild toxicities were achieved. This study provided evidence for using 4D-MRI guided SBRT as an alternative treatment in unresectable CRLM.
Collapse
Affiliation(s)
- H Z Wang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - X Zheng
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, Beijing, China
| | - J Sun
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, Beijing, China
| | - X Zhu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - D Dong
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, Beijing, China
| | - Y Du
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, Beijing, China
| | - Z Feng
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, Beijing, China
| | - J Gong
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, Beijing, China
| | - H Wu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, Beijing, China
| | - J Geng
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - S Li
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - M Song
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - Y Zhang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - Z Liu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - Y Cai
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - Y Li
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - W Wang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| |
Collapse
|
9
|
Li D, Song M, Zhang B, Li N, Yang J. [The mediating role of resilience between social capital at work and anxiety of medical staff]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2023; 41:672-675. [PMID: 37805427 DOI: 10.3760/cma.j.cn121094-20221116-00545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 10/09/2023]
Abstract
Objective: To explore the influence of social capital at work on anxiety of medical staff, and the mediating role of resilience. Methods: From March to May 2022, a total of 201 medical staff in the Affiliated Hospital of Jining Medical University were investigated with the General Information Questionnaire, Workplace Social Capital Scale, Connor-Davidson Resilience Scale (CD-RISC-10) and Generalized Anxiety Disorder-7 (GAD-7) . K-S method was used for normdity test of econometic voriobles, and normal distribution data were represented by Mean±SD, Pearson correlation analysis and linear regression analysis were used to test correlation between variables and mediating effect, and Bootstrap method was carried out by SPSS macro program PROCESS v3.5 to verify the mediating effect. Results: The detection rate of anxiety was 59.20% (119/201) in medical staff. The scores of social capital at work (28.90±5.83) and resilience (31.55±4.98) were negatively correlated with the score of anxiety (7.20±2.06) (r=-0.338, -0.510, P<0.001) , while the score of social capital at work was positively correlated with resilience (r=0.392, P<0.001) . Workplace social capital positively predicted resilience (β=0.392, P<0.001) , and both workplace social capital (β=-0.222, P=0.001) and resilience at work (β=-0.423, P<0.001) negatively predicted anxiety score. The direct effect of social capital in the workplace of medical staff on anxiety was -0.222 (95%CI: -0.349~-0.095, P=0.001) , and the indirect effect of resilience on anxiety was -0.166 (95%CI: -0.265~-0.080) . The resilience of medical staff had a partial mediating effect between workplace social capital and anxiety, which accounted for 42.78% of the total effect. Conclusion: The resilience of medical staff has a partial mediating effect between workplace social capital and anxiety. Workplace social capital can not only directly affect the anxiety of medical staff, but also indirectly affect it through resilience.
Collapse
Affiliation(s)
- D Li
- Department of Endocrine Genetic Metabolism, Affiliated Hospital of Jining Medical University, Jining 272001, China
| | - M Song
- Department of Endocrine Genetic Metabolism, Affiliated Hospital of Jining Medical University, Jining 272001, China
| | - B Zhang
- Department of Endocrine Genetic Metabolism, Affiliated Hospital of Jining Medical University, Jining 272001, China
| | - N Li
- Educational Institute of Behavioral Medicine, Jining Medical University, Jining 272013, China
| | - J Yang
- Educational Institute of Behavioral Medicine, Jining Medical University, Jining 272013, China
| |
Collapse
|
10
|
Yin S, Zhao S, Li J, Liu K, Ma X, Zhang Z, Wang R, Tian J, Liu F, Song Y, Song M, Zhao R, Yang R, Lee MH, Dong Z. NUMA1 modulates apoptosis of esophageal squamous cell carcinoma cells through regulating ASK1-JNK signaling pathway. Cell Mol Life Sci 2023; 80:211. [PMID: 37462735 DOI: 10.1007/s00018-023-04854-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Revised: 05/30/2023] [Accepted: 07/01/2023] [Indexed: 07/21/2023]
Abstract
Esophageal squamous cell carcinoma (ESCC) is a common malignancy worldwide with a low survival rate due to a lack of therapeutic targets. Here, our results showed that nuclear mitotic apparatus protein 1 (NUMA1) transcript and protein levels are significantly upregulated in ESCC patient samples and its high expression predicated poor prognosis. Knock-down of NUMA1 promoted cell apoptosis and suppressed cell proliferation and colony formation. By using cell-derived xenograft (CDX) and patient-derived xenograft (PDX) mice models, we found silencing the NUMA1 expression suppressed tumor progression. In addition, conditional knocking-out of NUMA1 reduced 4NQO-induced carcinogenesis in mice esophagus, which further confirmed the oncogenic role of NUMA1 in ESCC. Mechanistically, from the immunoprecipitation assay we revealed that NUMA1 interacted with GSTP1 and TRAF2, promoted the association of TRAF2 with GSTP1 while inhibited the interaction of TRAF2 and ASK1, thus to regulate sustained activation of JNK. In summary, our findings suggest that NUMA1 plays an important role during ESCC progression and it functions through regulating ASK1-MKK4-SAPK/JNK signaling pathway.
Collapse
Affiliation(s)
- Shuying Yin
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, Henan, China
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, 450008, Henan, China
| | - Simin Zhao
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, 450008, Henan, China
- Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
| | - Jian Li
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, 450008, Henan, China
| | - Kangdong Liu
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, Henan, China
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, 450008, Henan, China
| | - Xinli Ma
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, 450008, Henan, China
| | - Zihan Zhang
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, Henan, China
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, 450008, Henan, China
| | - Rui Wang
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, 450008, Henan, China
| | - Jie Tian
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, Henan, China
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, 450008, Henan, China
| | - Fangfang Liu
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, 450008, Henan, China
- Research Center of Basic Medicine Sciences, School of Basic Medical Sciences, AMS, Zhengzhou University, Zhengzhou, 450001, China
| | - Yanming Song
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, 450008, Henan, China
| | - Mengqiu Song
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, Henan, China
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, 450008, Henan, China
| | - Ran Zhao
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, Henan, China
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, 450008, Henan, China
| | - Ran Yang
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, 450008, Henan, China
| | - Mee-Hyun Lee
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, Henan, China.
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, 450008, Henan, China.
- College of Korean Medicine, Dongshin University, Naju, Jeonnam, 58245, Republic of Korea.
| | - Zigang Dong
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, Henan, China.
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, 450008, Henan, China.
- Department of Pathophysiology, School of Basic Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou, 450001, Henan, China.
| |
Collapse
|
11
|
Feng H, Liu H, Wang Q, Song M, Yang T, Zheng L, Wu D, Shao X, Shi G. Breast cancer diagnosis and prognosis using a high b-value non-Gaussian continuous-time random-walk model. Clin Radiol 2023:S0009-9260(23)00227-1. [PMID: 37344324 DOI: 10.1016/j.crad.2023.05.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Revised: 05/11/2023] [Accepted: 05/19/2023] [Indexed: 06/23/2023]
Abstract
AIM To compare the diagnostic performance of mono-exponential model-derived apparent diffusion coefficient (ADC), continuous-time random-walk (CTRW) model-derived Dm, α, β and their combinations in discriminating malignancy of breast lesions, and investigate the association between model-derived parameters and prognosis-related immunohistochemical indices. MATERIALS AND METHODS A total of 85 patients with breast lesions (51 malignant, 34 benign) were analysed in this retrospective study. Clinical characteristics include oestrogen receptor (ER), progesterone receptor (PR), human epidermal receptor 2 (HER2), and Ki-67. The ADC was fitted using a mono-exponential model (b-values = 0, 800 s/mm2), while Dm, α, and β were fitted using a CTRW model. Independent Student's t-test and the Mann-Whitney U-test were used for the comparison of parameters. Discrimination performance was accomplished by receiver operating characteristic (ROC) analysis, and Spearman's correlation analysis was used to explore the association between immunohistochemical indices and diffusion parameters, the statistical significance level was p<0.05. RESULTS Dm and ADC demonstrated similar performance in differentiating malignant and benign lesions (AUC = 0.928 versus 0.930), while the combination of Dm, α, and β could improve the AUC to 0.969. The combined parameter generated by ADC, Dm, α, and β was effective in identifying the ER+/ER- and PR+/PR- patients. Temporal heterogeneity parameter α correlated significantly with the expression of PR. CONCLUSION Diffusion parameters derived from the CTRW model could effectively discriminate the malignancy of breast lesions. Meanwhile, the hormone receptor expression could be distinguished by combined diffusion parameters, and have the potential to reflect the prognosis.
Collapse
Affiliation(s)
- H Feng
- Department of Radiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
| | - H Liu
- Department of Radiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Q Wang
- Department of Radiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
| | - M Song
- Department of Radiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
| | - T Yang
- Shenzhen United Imaging Research Institute of Innovative Medical Equipment, Shenzhen, China
| | - L Zheng
- Shenzhen United Imaging Research Institute of Innovative Medical Equipment, Shenzhen, China
| | - D Wu
- Shanghai Key Laboratory of Magnetic Resonance, School of Physics and Electronics Science, East China Normal University, Shanghai, China
| | - X Shao
- Department of Anesthesiology, The Fourth Hospital of Shijiazhuang, Shijiazhuang, China
| | - G Shi
- Department of Radiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
| |
Collapse
|
12
|
Song M, Pang L, Zhang M, Qu Y, Laster KV, Dong Z. Cdc2-like kinases: structure, biological function, and therapeutic targets for diseases. Signal Transduct Target Ther 2023; 8:148. [PMID: 37029108 PMCID: PMC10082069 DOI: 10.1038/s41392-023-01409-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2022] [Revised: 03/15/2023] [Accepted: 03/20/2023] [Indexed: 04/09/2023] Open
Abstract
The CLKs (Cdc2-like kinases) belong to the dual-specificity protein kinase family and play crucial roles in regulating transcript splicing via the phosphorylation of SR proteins (SRSF1-12), catalyzing spliceosome molecular machinery, and modulating the activities or expression of non-splicing proteins. The dysregulation of these processes is linked with various diseases, including neurodegenerative diseases, Duchenne muscular dystrophy, inflammatory diseases, viral replication, and cancer. Thus, CLKs have been considered as potential therapeutic targets, and significant efforts have been exerted to discover potent CLKs inhibitors. In particular, clinical trials aiming to assess the activities of the small molecules Lorecivivint on knee Osteoarthritis patients, and Cirtuvivint and Silmitasertib in different advanced tumors have been investigated for therapeutic usage. In this review, we comprehensively documented the structure and biological functions of CLKs in various human diseases and summarized the significance of related inhibitors in therapeutics. Our discussion highlights the most recent CLKs research, paving the way for the clinical treatment of various human diseases.
Collapse
Affiliation(s)
- Mengqiu Song
- Department of Pathophysiology, School of Basic Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou, Henan, 450001, China
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, Henan, 450008, China
- State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University, Zhengzhou, Henan, China
| | - Luping Pang
- State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University, Zhengzhou, Henan, China
- Academy of Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou, Henan, 450001, China
- Research Center of Basic Medicine, Academy of Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou, Henan, 450001, China
| | - Mengmeng Zhang
- Department of Pathophysiology, School of Basic Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou, Henan, 450001, China
- Academy of Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou, Henan, 450001, China
| | - Yingzi Qu
- Department of Pathophysiology, School of Basic Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou, Henan, 450001, China
- Academy of Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou, Henan, 450001, China
| | - Kyle Vaughn Laster
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, Henan, 450008, China
| | - Zigang Dong
- Department of Pathophysiology, School of Basic Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou, Henan, 450001, China.
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, Henan, 450008, China.
- State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University, Zhengzhou, Henan, China.
- Academy of Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou, Henan, 450001, China.
| |
Collapse
|
13
|
Yang M, Zhang Q, Ge Y, Tang M, Hu C, Wang Z, Zhang X, Song M, Ruan G, Zhang X, Liu T, Xie H, Zhang H, Zhang K, Li Q, Li X, Liu X, Lin S, Shi H. Prognostic Roles Of Inflammation- And Nutrition-Based Indicators For Female Patients With Cancer. Clin Nutr ESPEN 2023. [DOI: 10.1016/j.clnesp.2022.09.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/28/2023]
|
14
|
Song M, Shi H. The Advanced Lung Cancer Inflammation Index Is The Optimal Inflammatory Biomarker Of Overall Survival In Patients With Lung Cancer. Clin Nutr ESPEN 2023. [DOI: 10.1016/j.clnesp.2022.09.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023]
|
15
|
Kahan R, Gao Q, Zhang M, Abraham N, Gonzalez T, Song M, Carney J, Alderete I, Asokan A, Barbas A, Hartwig M. AAV9 PD-L1 Mediated Immunodulation of Donor Graft in Rat Lung Allotransplantation. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
16
|
Gu T, Tian X, Wang Y, Yang W, Li W, Song M, Zhao R, Wang M, Gao Q, Li T, Zhang C, Kundu JK, Liu K, Dong Z, Lee MH. Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint. Front Immunol 2023; 14:1145028. [PMID: 37205112 PMCID: PMC10185823 DOI: 10.3389/fimmu.2023.1145028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2023] [Accepted: 04/10/2023] [Indexed: 05/21/2023] Open
Abstract
Immunotherapy has emerged as an effective therapeutic approach to several cancer types. The reinvigoration of tumor-infiltrating lymphocyte-mediated immune responses via the blockade of immune checkpoint markers, such as program cell death-1 (PD-1) or its cognate ligand PD-L1, has been the basis for developing clinically effective anticancer therapies. We identified pentamidine, an FDA-approved antimicrobial agent, as a small-molecule antagonist of PD-L1. Pentamidine enhanced T-cell-mediated cytotoxicity against various cancer cells in vitro by increasing the secretion of IFN-γ, TNF-α, perforin, and granzyme B in the culture medium. Pentamidine promoted T-cell activation by blocking the PD-1/PD-L1 interaction. In vivo administration of pentamidine attenuated the tumor growth and prolonged the survival of tumor-bearing mice in PD-L1 humanized murine tumor cell allograft models. Histological analysis of tumor tissues showed an increased number of tumor-infiltrating lymphocytes in tissues derived from pentamidine-treated mice. In summary, our study suggests that pentamidine holds the potential to be repurposed as a novel PD-L1 antagonist that may overcome the limitations of monoclonal antibody therapy and can emerge as a small molecule cancer immunotherapy.
Collapse
Affiliation(s)
- Tingxuan Gu
- Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, China
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Xueli Tian
- Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, China
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Yuanyuan Wang
- Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, China
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Wenqian Yang
- Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, China
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Wenwen Li
- Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, China
| | - Mengqiu Song
- Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, China
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Ran Zhao
- Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, China
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Mengqiao Wang
- Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, China
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Quanli Gao
- Department of Immunology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
| | - Tiepeng Li
- Department of Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
| | - Chengjuan Zhang
- Department of Immunology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
| | - Joydeb Kumar Kundu
- Li Ka Shing Applied Virology Institute, University of Alberta, Edmonton, AB, Canada
| | - Kangdong Liu
- Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, China
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
- Henan Provincial Cooperative Innovation Center for Cancer Chemoprevention, Zhengzhou University, Zhengzhou, China
| | - Zigang Dong
- Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, China
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
- *Correspondence: Zigang Dong, ; Mee-Hyun Lee,
| | - Mee-Hyun Lee
- Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, China
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
- Henan Provincial Cooperative Innovation Center for Cancer Chemoprevention, Zhengzhou University, Zhengzhou, China
- College of Korean Medicine, Dongshin University, Naju, Republic of Korea
- *Correspondence: Zigang Dong, ; Mee-Hyun Lee,
| |
Collapse
|
17
|
Wang J, Xu HB, Qiao SB, Guan FH, Hu WX, Yang JS, Yuan JG, Cui L, Song M, Zhang P, Xu B. [Predictive value of SYNTAX-Ⅱ score on prognosis of patients with chronic total occlusion undergoing percutaneous coronary intervention]. Zhonghua Xin Xue Guan Bing Za Zhi 2022; 50:1186-1192. [PMID: 36517439 DOI: 10.3760/cma.j.cn112148-20221101-00848] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/17/2023]
Abstract
Objective: To investigate the predictive value of SYNTAX-Ⅱ score on long term prognosis of patients diagnosed with chronic total occlusion (CTO) and received percutaneous coronary intervention (PCI). Methods: Patients undergoing CTO-PCI in Fuwai hospital from January 2010 to December 2013 were enrolled in this retrospective analysis. The SYNTAX-Ⅱ score of the patients was calculated. According to SYNTAX-Ⅱ score tertiles, patients were stratified as follows: SYNTAX-Ⅱ≤20, 20<SYNTAX-Ⅱ≤27, SYNTAX-Ⅱ>27. Primary endpoint was major adverse cardiac events (MACCE), including all-cause death, myocardial infarction, stroke and any revascularization. Secondary endpoints included stent thrombosis, heart failure and target lesion failure (TLF). Patients were followed up by outpatient visit or telephone call at 1 month, 6 months and 1 year after PCI, and annually up to 5 years. Multivariate Cox regression model was used to analyze the independent risk factors of all-cause death in patients undergoing CTO-PCI. The predictive value of SYNTAX score with SYNTAX-Ⅱ score for all-cause death was evaluated by the receiver operating characteristic (ROC) curve and the area under the curve (AUC). Results: A total of 2 391 patients with CTO and received PCI were enrolled in this study. The mean age was (57.0±10.5) years, 1 994 (83.40%) patients were male. There were 802 patients in lower tertile group (SYNTAX-Ⅱ≤20), 798 patients in intermediate group (20<SYNTAX-Ⅱ≤27) and 791 patients in upper tertile group (SYNTAX-Ⅱ>27). At the end of 5-year follow-up, the loss to follow-up rate of the three groups was 9.10%(73/802), 10.78%(86/798)and 8.85%(70/791), respectively. The rate of all-cause mortality (1.78% (13/729) vs. 3.65% (26/712) vs. 9.02% (65/721), P<0.001), cardiac death (1.37% (10/729) vs. 2.11% (15/712) vs. 4.85% (35/721), P<0.001), target vessel myocardial infarctions (4.25% (31/729) vs. 4.49% (32/712) vs. 7.07% (51/721), P=0.03), probable stent thrombosis (1.51% (11/729) vs. 2.81% (20/712) vs. 3.61% (26/721), P=0.04) and heart failure (1.78% (13/729) vs. 1.97% (14/712) vs. 5.41% (39/721), P<0.001) increased in proportion to increasing SYNTAX-Ⅱ score (all P<0.05). Multivariable Cox regression analysis indicated that female (HR=2.05, 95%CI 1.12-3.73, P=0.01), left ventricular ejection fraction (HR=0.97, 95%CI 0.95-1.00, P=0.05) and SYNTAX-Ⅱ score (HR=1.07, 95%CI 1.02-1.11,P=0.01) were independent predictors for all-cause mortality in patients undergoing CTO-PCI. The predicted value of the SYNTAX-Ⅱ score for all-cause death was significantly higher than the SYNTAX score (AUC 0.71 vs. 0.60, P=0.003). Conclusion: For CTO patients who underwent percutaneous coronary intervention, SYNTAX-Ⅱ score is an independent predictor for 5-year all-cause death, and SYNTAX-Ⅱ serves as an important predictor for all-cause death in these patients.
Collapse
Affiliation(s)
- J Wang
- Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| | - H B Xu
- Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| | - S B Qiao
- Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| | - F H Guan
- Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| | - W X Hu
- Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| | - J S Yang
- Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| | - J G Yuan
- Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| | - L Cui
- Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| | - M Song
- Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| | - P Zhang
- CCRF (Beijing) Inc, Beijing 100027, China
| | - Bo Xu
- Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
| |
Collapse
|
18
|
Nolan GS, Dunne JA, Lee AE, Wade RG, Kiely AL, Pritchard Jones RO, Gardiner MD, Abbassi O, Abdelaty M, Ahmed F, Ahmed R, Ali S, Allan A, Allen L, Anderson I, Bakir A, Berwick D, Sarala BBN, Bhat W, Bloom O, Bolton L, Brady N, Campbell E, Capitelli-McMahon H, Cassell O, Chalhoub X, Chalmers R, Chan J, Chu HO, Collin T, Cooper K, Curran TA, Cussons D, Daruwalla M, Dearden A, Delikonstantinou I, Dobbs T, Dunlop R, El-Muttardi N, Eleftheriadou A, Elamin SE, Eriksson S, Exton R, Fourie LR, Freethy A, Gardner E, Geh JL, Georgiou A, Georgiou M, Gilbert P, Gkorila A, Green D, Haeney J, Hamilton S, Harper F, Harrison C, Heinze Z, Hemington-Gorse S, Hever P, Hili S, Holmes W, Hughes W, Ibrahim N, Ismail A, Jallali N, James NK, Jemec B, Jica R, Kaur A, Kazzazi D, Khan M, Khan N, Khashaba H, Khera B, Khoury A, Kiely J, Kumar S, Patel PK, Kumbasar DE, Kundasamy P, Kyle D, Langridge B, Liu C, Lo M, Macdonald C, Anandan SM, Mahdi M, Mandal A, Manning A, Markeson D, Matteucci P, McClymont L, Mikhail M, Miller MC, Munro S, Musajee A, Nasrallah F, Ng L, Nicholas R, Nicola A, Nikkhah D, O'Hara N, Odili J, Oudit D, Patel A, Patel C, Patel N, Patel P, Peach H, Phillips B, Pinder R, Pinto-Lopes R, Plonczak A, Quinnen N, Rafiq S, Rahman K, Ramjeeawon A, Rinkoff S, Sainsbury D, Schumacher K, Segaren N, Shahzad F, Shariff Z, Siddiqui A, Singh P, Sludden E, Smith JRO, Song M, Stodell M, Tanos G, Taylor K, Taylor L, Thomson D, Tiernan E, Totty JP, Vaingankar N, Toh V, Wensley K, Whitehead C, Whittam A, Wiener M, Wilson A, Wong KY, Wood S, Yeoh T, Yii NW, Yim G, Young R, Zberea D, Jain A. National audit of non-melanoma skin cancer excisions performed by plastic surgery in the UK. Br J Surg 2022; 109:1040-1043. [DOI: 10.1093/bjs/znac232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Accepted: 05/30/2022] [Indexed: 11/13/2022]
Abstract
A national, multi-centre audit of non-melanoma skin cancer excisions by plastic surgery.
Collapse
Affiliation(s)
- Grant S Nolan
- Department of Plastic and Reconstructive Surgery, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Trust , Fulwood, Preston , UK
| | - Jonathan A Dunne
- Department of Plastic and Reconstructive Surgery, Charing Cross and St Mary’s Hospitals, Imperial College Healthcare NHS Trust , London , UK
| | - Alice E Lee
- Department of Plastic and Reconstructive Surgery, Charing Cross and St Mary’s Hospitals, Imperial College Healthcare NHS Trust , London , UK
| | - Ryckie G Wade
- Leeds Institute for Medical Research, University of Leeds , Leeds , UK
- Department of Plastic and Reconstructive Surgery, Leeds Teaching Hospitals NHS Trust , Leeds , UK
| | - Ailbhe L Kiely
- Department of Plastic and Reconstructive Surgery, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Trust , Fulwood, Preston , UK
| | - Rowan O Pritchard Jones
- Department of Plastic and Reconstructive Surgery, Whiston Hospital, St Helens and Knowsley Teaching Hospitals NHS Trust , Prescot , UK
| | - Matthew D Gardiner
- Department of Plastic and Reconstructive Surgery, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Wexham , Slough , UK
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford , Oxford , UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Abhilash Jain
- Department of Plastic and Reconstructive Surgery, Charing Cross and St Mary’s Hospitals, Imperial College Healthcare NHS Trust , London , UK
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford , Oxford , UK
| | | |
Collapse
|
19
|
Wang Y, Liu X, Guo C, Xiong Y, Cao L, Bing Z, Song Y, Gao C, Tian Z, Lin Y, Xu Y, Xue J, Li B, Huang Z, Yang X, Cao Z, Li J, Jiang X, Si X, Zhang L, Song M, Zhou Z, Chen R, Li S, Yang H, Liang N. EP16.01-017 T-cell Repertoire Heterogeneity and Homogeneity in Synonymous Multiple Primary Lung Cancers. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.1017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
20
|
Song M, Liu Y, Wang XJ, Zhang LW, Liu Q, Chen TF, Su X, Li WW, Lyu LX, Yang YF. [Association of glutamate receptor metabotropic 5 polymorphisms with schizophrenia susceptibility in a Chinese Han population]. Zhonghua Yi Xue Za Zhi 2022; 102:2108-2114. [PMID: 35844113 DOI: 10.3760/cma.j.cn112137-20211125-02631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objectives: To investigate the association of single nucleotide polymorphisms (SNP) of glutamate receptor metabotropic 5 (GRM5) gene with schizophrenia susceptibility(SZ) in a Chinese Han population. Methods: Twenty-two SNPs located in GRM5 gene in 528 paranoid SZ patients and 528 control subjects recruited from northern Henanwere analyzed. The clinical features of 267 first-episode SZ patients were assessed with the Positive and Negative Syndrome Scale (PANSS). Results: The SZ group included 264 males and 264 females, aged (27±8) years; the healthy control group had 264 males and 264 females, aged (28±8) years.The differences in the genotypic and allelic frequencies of two SNPs (rs567990 and rs12421343) were statistically significant between the SZ patients and control groups (all P<0.05). The allele frequency of rs504183 was also statistically different between the two groups (P=0.030). When the subjects were stratified by sex, the genotypic and allelic frequencies of rs12421343 in female subjects were statistically different between the SZ patients and control groups. The allele frequencies of SNPs (rs12422021, rs567990, and rs7101540) were also statisticallydifferent between the two groups (all P<0.05). Meanwhile, rs567990 AG+GG carriers had a higher risk for SZ than AA carriers in female subjects(OR=1.946, 95%CI: 1.264-2.995). In addition, the patients with different genotypes (GG, AA+AG) of rs12422021 showed statistically significant differences in PANSS total score(84.8±24.4 vs 75.3±18.6), positive (16.2±4.3 vs 14.4±4.2), excitement (12.4±5.1 vs 10.2±4.1) and cognitive impairment factor scores (15.2±6.8 vs 13.3±3.9) (all P<0.05). The patients with AC and the other two genotypes (AA and CC) of rs504183 showed statistically significant differences in PANSS negative factor score(27.4±9.9 vs 24.7±8.4 and 23.4±8.1, both P<0.05). Conclusion: The current study provides further evidence that GRM5 is associated with SZ, and suggests a putative sex difference.
Collapse
Affiliation(s)
- M Song
- Department of Psychiatry, the Second Affiliated Hospital of Xinxiang Medical University, Henan Mental Hospital, Henan Key Lab of Biological Psychiatry, Xinxiang 453002, China
| | - Y Liu
- Department of Psychiatry, the Second Affiliated Hospital of Xinxiang Medical University, Henan Mental Hospital, Henan Key Lab of Biological Psychiatry, Xinxiang 453002, China
| | - X J Wang
- Department of Psychiatry, the Second Affiliated Hospital of Xinxiang Medical University, Henan Mental Hospital, Henan Key Lab of Biological Psychiatry, Xinxiang 453002, China
| | - L W Zhang
- Department of Psychiatry, the Second Affiliated Hospital of Xinxiang Medical University, Henan Mental Hospital, Henan Key Lab of Biological Psychiatry, Xinxiang 453002, China
| | - Q Liu
- Department of Psychiatry, the Second Affiliated Hospital of Xinxiang Medical University, Henan Mental Hospital, Henan Key Lab of Biological Psychiatry, Xinxiang 453002, China
| | - T F Chen
- Department of Psychiatry, the Second Affiliated Hospital of Xinxiang Medical University, Henan Mental Hospital, Henan Key Lab of Biological Psychiatry, Xinxiang 453002, China
| | - X Su
- Department of Psychiatry, the Second Affiliated Hospital of Xinxiang Medical University, Henan Mental Hospital, Henan Key Lab of Biological Psychiatry, Xinxiang 453002, China
| | - W W Li
- Department of Psychiatry, the Second Affiliated Hospital of Xinxiang Medical University, Henan Mental Hospital, Henan Key Lab of Biological Psychiatry, Xinxiang 453002, China
| | - L X Lyu
- Department of Psychiatry, the Second Affiliated Hospital of Xinxiang Medical University, Henan Mental Hospital, Henan Key Lab of Biological Psychiatry, Xinxiang 453002, China
| | - Y F Yang
- Department of Psychiatry, the Second Affiliated Hospital of Xinxiang Medical University, Henan Mental Hospital, Henan Key Lab of Biological Psychiatry, Xinxiang 453002, China
| |
Collapse
|
21
|
Zhang X, Yang ZY, Yang AK, Zhang Q, Li QL, Chen SW, Chen JT, Song M. [The clinical value of oral robotic surgery in the treatment of oropharyngeal squamous cell carcinoma]. Zhonghua Zhong Liu Za Zhi 2022; 44:570-576. [PMID: 35754232 DOI: 10.3760/cma.j.cn112152-20200731-00698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objective: To explore the therapeutic effects of transoral robotic surgery (TORS) and traditional surgical modes in oropharyngeal squamous cell carcinoma (OPSCC). Methods: The clinicopathological data of patients with oropharyngeal squamous cell carcinoma treated at Sun Yat-sen University Cancer Center from 2010 to 2018 were retrospectively analyzed. 135 cases were treated with traditional surgery (non-TORS group), while 52 cases were treated with TORS (TORS group). The prognosis of the two groups of patients were analyzed by Kaplan-Meier method and Log rank test, the influencing factors were analyzed by Cox regression model. Results: The 2-year overall survival (OS, 94.2%) and 2-year progression-free survival (PFS, 93.8%) of patients in the TORS group were better than those in the non-TORS group (71.4% and 71.4%, respectively, P<0.05). The 2-year OS (93.3%) and 2-year PFS (92.8%) of TORS group patients in T1-2 stage were better than those of non-TORS group (73.1% and 72.8%, respectively, P<0.05). The 2-year OS (95.8%) and 2-year PFS (95.2%) of patients with stage Ⅰ to Ⅱ in the TORS group were not significantly different from those in the non-TORS group (84.1% and 83.9%, respectively, P>0.05). The 2-year OS (92.9%) and 2-year PFS rate (92.7%) of patients with stage Ⅲ to Ⅳ in the TORS group were better than those in the non-TORS group (64.7% and 63.9%, respectively, P<0.05). The 2-year OS (94.4%) of HPV-positive patients in the TORS group was not significantly different from that in the non-TORS group (83.3%, P=0.222). The 2-year OS of HPV-negative patients in the TORS group (94.1%) was significantly different from that in the non-TORS group (43.7%, P<0.001). HPV status was an independent prognostic factor (P=0.008). Conclusions: TORS has a better prognosis in the treatment of oropharyngeal squamous cell carcinoma compared with the traditional treatment methods. The patients with T1-T2 can achieve better survival benefits after TORS treatment. The HPV-positive OPSCC patients has a better prognosis than that of HPV-negative OPSCC patients, and regardless of HPV status, OPSCC patients in the TORS group could obtain a better survival prognosis.
Collapse
Affiliation(s)
- X Zhang
- Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - Z Y Yang
- Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - A K Yang
- Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - Q Zhang
- Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - Q L Li
- Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - S W Chen
- Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - J T Chen
- Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - M Song
- Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| |
Collapse
|
22
|
Sabharwall P, Hartvigsen JL, Morton TJ, Yoo J, Qin S, Song M, Guillen DP, Unruh T, Hansel JE, Jackson J, Gehin J, Trellue H, Mascarenas D, Reid RS, Petrie CM. Nonnuclear Experimental Capabilities to Support Design, Development, and Demonstration of Microreactors. NUCL TECHNOL 2022. [DOI: 10.1080/00295450.2022.2043087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- P. Sabharwall
- Idaho National Laboratory, Nuclear Systems Design and Analysis Division, 1955 N. Fremont Avenue, Idaho Falls, Idaho 83415
| | - J. L. Hartvigsen
- Idaho National Laboratory, Nuclear Systems Design and Analysis Division, 1955 N. Fremont Avenue, Idaho Falls, Idaho 83415
| | - T. J. Morton
- Idaho National Laboratory, Nuclear Systems Design and Analysis Division, 1955 N. Fremont Avenue, Idaho Falls, Idaho 83415
| | - J. Yoo
- Idaho National Laboratory, Nuclear Systems Design and Analysis Division, 1955 N. Fremont Avenue, Idaho Falls, Idaho 83415
| | - S. Qin
- Idaho National Laboratory, Nuclear Systems Design and Analysis Division, 1955 N. Fremont Avenue, Idaho Falls, Idaho 83415
| | - M. Song
- Idaho National Laboratory, Nuclear Systems Design and Analysis Division, 1955 N. Fremont Avenue, Idaho Falls, Idaho 83415
| | - D. P. Guillen
- Idaho National Laboratory, Nuclear Systems Design and Analysis Division, 1955 N. Fremont Avenue, Idaho Falls, Idaho 83415
| | - T. Unruh
- Idaho National Laboratory, Nuclear Systems Design and Analysis Division, 1955 N. Fremont Avenue, Idaho Falls, Idaho 83415
| | - J. E. Hansel
- Idaho National Laboratory, Nuclear Systems Design and Analysis Division, 1955 N. Fremont Avenue, Idaho Falls, Idaho 83415
| | - J. Jackson
- Idaho National Laboratory, Nuclear Systems Design and Analysis Division, 1955 N. Fremont Avenue, Idaho Falls, Idaho 83415
| | - J. Gehin
- Idaho National Laboratory, Nuclear Systems Design and Analysis Division, 1955 N. Fremont Avenue, Idaho Falls, Idaho 83415
| | - H. Trellue
- Los Alamos National Laboratory, Post Office Box 1663, Los Alamos, New Mexico 87545
| | - D. Mascarenas
- Los Alamos National Laboratory, Post Office Box 1663, Los Alamos, New Mexico 87545
| | - R. S. Reid
- Los Alamos National Laboratory, Post Office Box 1663, Los Alamos, New Mexico 87545
| | - C. M. Petrie
- Oak Ridge National Laboratory, Nuclear Energy and Fuel Cycle Division, Post Office Box 2008, Oak Ridge, Tennessee 37831
| |
Collapse
|
23
|
Abstract
Exposed dental pulp can maintain its vitality through a pulp-capping procedure with biocompatible materials, followed by reparative dentin formation. Our previous study demonstrated that a vitronectin-derived peptide (VnP-16) promotes osteoblast differentiation and concomitantly restrains osteoclast differentiation and resorptive function. In this study, we aimed to demonstrate that VnP-16 promotes odontoblast differentiation, mineralization, and reparative dentin formation in a pulp exposure model using a rat tooth. VnP-16 showed no cytotoxicity and promoted cellular behavior in human dental pulp cells, enhancing their differentiation into odontoblast-like cells and mineralization, effects that are comparable to those obtained with vitronectin. In a rat pulp exposure model, VnP-16 showed mild inflammatory responses at 2 and 4 wk or none. Mineral trioxide aggregate (MTA) demonstrated a tendency of early formation of reparative dentin at 2 wk when compared with recombinant human bone morphogenetic protein 2 (rhBMP-2) and VnP-16. However, VnP-16 induced reparative dentin formation similar to MTA and rhBMP-2 without inflammation at 4 wk. In addition, VnP-16 showed a thicker and homogeneous reparative dentin formation versus MTA and rhBMP-2. Collectively, these results suggest that VnP-16 can be a useful, direct pulp-capping agent for highly qualified reparative dentin formation by promoting cell behavior and odontoblastic differentiation of human dental pulp cells.
Collapse
Affiliation(s)
- C Park
- Department of Oral Biochemistry and Program in Cancer and Developmental Biology, Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Korea.,Department of Conservative Dentistry and Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Korea
| | - M Song
- Department of Conservative Dentistry, College of Dentistry, Dankook University, Cheon-An, Korea
| | - S Y Kim
- Department of Conservative Dentistry and Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Korea
| | - B M Min
- Department of Oral Biochemistry and Program in Cancer and Developmental Biology, Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Korea
| |
Collapse
|
24
|
Guimbao J, Sanchis L, Weituschat L, Manuel Llorens J, Song M, Cardenas J, Aitor Postigo P. Numerical Optimization of a Nanophotonic Cavity by Machine Learning for Near-Unity Photon Indistinguishability at Room Temperature. ACS Photonics 2022; 9:1926-1935. [PMID: 35726240 PMCID: PMC9205277 DOI: 10.1021/acsphotonics.1c01651] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/27/2021] [Indexed: 05/25/2023]
Abstract
Room-temperature (RT), on-chip deterministic generation of indistinguishable photons coupled to photonic integrated circuits is key for quantum photonic applications. Nevertheless, high indistinguishability (I) at RT is difficult to obtain due to the intrinsic dephasing of most deterministic single-photon sources (SPS). Here, we present a numerical demonstration of the design and optimization of a hybrid slot-Bragg nanophotonic cavity that achieves a theoretical near-unity I and a high coupling efficiency (β) at RT for a variety of single-photon emitters. Our numerical simulations predict modal volumes in the order of 10-3(λ/2n)3, allowing for strong coupling of quantum photonic emitters that can be heterogeneously integrated. We show that high I and β should be possible by fine-tuning the quality factor (Q) depending on the intrinsic properties of the single-photon emitter. Furthermore, we perform a machine learning optimization based on the combination of a deep neural network and a genetic algorithm (GA) to further decrease the modal volume by almost 3 times while relaxing the tight dimensions of the slot width required for strong coupling. The optimized device has a slot width of 20 nm. The design requires fabrication resolution in the limit of the current state-of-the-art technology. Also, the condition for high I and β requires a positioning accuracy of the quantum emitter at the nanometer level. Although the proposal is not a scalable technology, it can be suitable for experimental demonstration of single-photon operation.
Collapse
Affiliation(s)
- J. Guimbao
- Instituto
de Micro y Nanotecnología, IMN-CNM,
CSIC (CEI UAM+CSIC), Tres Cantos, Madrid E-28760, Spain
| | - L. Sanchis
- Instituto
de Micro y Nanotecnología, IMN-CNM,
CSIC (CEI UAM+CSIC), Tres Cantos, Madrid E-28760, Spain
| | - L. Weituschat
- Instituto
de Micro y Nanotecnología, IMN-CNM,
CSIC (CEI UAM+CSIC), Tres Cantos, Madrid E-28760, Spain
| | - J. Manuel Llorens
- Instituto
de Micro y Nanotecnología, IMN-CNM,
CSIC (CEI UAM+CSIC), Tres Cantos, Madrid E-28760, Spain
| | - M. Song
- The
Institute of Optics, University of Rochester, Rochester, New York 14627, United States
| | - J. Cardenas
- The
Institute of Optics, University of Rochester, Rochester, New York 14627, United States
| | - P. Aitor Postigo
- Instituto
de Micro y Nanotecnología, IMN-CNM,
CSIC (CEI UAM+CSIC), Tres Cantos, Madrid E-28760, Spain
- The
Institute of Optics, University of Rochester, Rochester, New York 14627, United States
| |
Collapse
|
25
|
Chen SW, Zhang X, Li JJ, Li H, Yang AK, Zhang Q, Li QL, Chen WK, He LJ, Yang ZY, Song M. [Retropharyngeal lymph node dissection in head and neck cancers treated with transoral robotic surgery]. Zhonghua Zhong Liu Za Zhi 2022; 44:446-449. [PMID: 35615803 DOI: 10.3760/cma.j.cn112152-20200907-00803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objective: To evaluate the indications, safety, feasibility, and surgical technique for patients with head and neck cancers undergoing transoral robotic retropharyngeal lymph node (RPLN) dissection. Methods: The current study enrolled 12 consecutive head and neck cancer patients (seven males and four females) who underwent transoral robotic RPLN dissection with the da Vinci surgical robotic system at the Sun Yat-sen University Cancer Center from May 2019 to July 2020. Seven patients were diagnosed as nasopharyngeal carcinoma with RPLN metastasis after initial treatments, 4 patients were diagnosed as thyroid carcinoma with RPLN metastasis after initial treatments, and one patient was diagnosed as oropharyngeal carcinoma with RPLN metastasis before initial treatments. The operation procedure and duration time, intraoperative blood loss volume and complications, nasogastric feeding tube dependence, tracheostomy dependence, postoperative complications, and hospitalization time were recorded and analyzed. Results: All patients were successfully treated by transoral robotic dissection of the metastatic RPLNs, none of which was converted to open surgery. RPLNs were completely resected in 10 patients, and partly resected in 2 patients (both were nasopharyngeal carcinoma patients). The mean number of RPLN dissected was 1.7. The operation duration time and intraoperative blood loss volume were (191.3±101.1) min and (150.0±86.6) ml, respectively. There was no severe intraoperative complication such as massive haemorrhage or adjacent organ injury during surgery. Nasogastric tube use was required in all patients with (17.1±10.6) days of dependence, while tracheotomy was performed in 8 patients with (11.6±10.7) days of dependence. The postoperative hospitalization stay was (8.5±5.7) days. Postoperative complications occurred in 4 patients, including 2 of retropharyngeal incision and 2 of dysphagia. During a follow-up of (6.5±5.1) months, disease-free progression was observed in all patients, 10 patients were disease-free survival and other 2 patients were survival with tumor burden. Conclusions: The transoral robotic RPLN dissection is safety and feasible. Compared with the traditional open surgical approach, it is less traumatic and safer, has fewer complications and good clinical application potentiality. The indications for transoral robotic RPLN dissection include thyroid carcinoma, oropharyngeal carcinoma, and some selected nasopharyngeal carcinoma and other head and neck cancers. Metastatic RPLNs from some nasopharyngeal carcinoma with incomplete capsule, unclear border and adhesion to the surrounding vessels are not suitable for transoral robotic RPLN dissection.
Collapse
Affiliation(s)
- S W Chen
- Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - X Zhang
- Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - J J Li
- Department of Endoscopy, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - H Li
- Department of Radiology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - A K Yang
- Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - Q Zhang
- Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - Q L Li
- Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - W K Chen
- Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - L J He
- Department of Endoscopy, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - Z Y Yang
- Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - M Song
- Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| |
Collapse
|
26
|
Zhang X, Chen SW, Yang ZY, Chen JT, Su X, Yang AK, Song M. [Application of transoral robotic surgery in treatment of oropharyngeal squamous cell carcinoma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2022; 57:545-551. [PMID: 35610671 DOI: 10.3760/cma.j.cn115330-20210731-00505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objective: To evaluate the therapeutic and prognostic outcomes of transoral robotic surgery (TORS) for oropharyngeal squamous cell carcinoma (OSCC). Methods: A retrospective study of 99 OSCC patients treated with TORS in Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center between April 2017 and May 2021 was conducted. There were 84 males and 15 females, with an age range of 35-85 years. Patients' clinical characteristics, including clinical staging, HPV infection status, perioperative management and postoperative adjuvant treatment, were recorded. The overall survival (OS) and progression-free survival (PFS) were analyzed. The survival outcomes were analyzed with Kaplan-Meier method and Log-rank test. Results: The hospital stay of OSCC patients with TORS was (5.3±2.9) days and the average time of postoperative nasal feeding tube indwelling was (15.2±10.8) days. Among the 99 patients, 21 (21.2%) received tracheotomy and the average time of tracheotomy tube indwelling was (11.9±11.4) days. The two-year OS and PFS in patients with follow-up over two years were 94.0% and 87.7%, respectively and the three-year OS and PFS of patients with follow-up over three years were 94.0% and 78.9%, respectively. The two-year OS and PFS were respectively 97.4% and 88.9%, for patients with stages I-II and 86.8% and 88.9% for patients with stages III-IV. HPV-negative and HPV-positive patients had respectively two-year OS (100.0% vs. 91.5%) and PFS (88.9% vs. 87.2%). There was no significantly statistical difference in survival between patients with and without adjuvant radiotherapy after TORS (82.6% vs. 90.5%, HR=0.52, 95%CI: 0.12-2.23, P=0.400). Conclusions: TORS is more suitable for the treatment of patients with early (Ⅰ-Ⅱ) or HPV-positive oropharyngeal squamous cell carcinoma, and the recovery after TORS treatment is good.
Collapse
Affiliation(s)
- X Zhang
- Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
| | - S W Chen
- Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
| | - Z Y Yang
- Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
| | - J T Chen
- Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
| | - X Su
- Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
| | - A K Yang
- Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
| | - M Song
- Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
| |
Collapse
|
27
|
Meng Y, Lian YB, Xu Y, Dong JQ, Song M. [Clinical and molecular pathological features of bronchopulmonary large cell neuroendocrine carcinoma]. Zhonghua Yi Xue Za Zhi 2022; 102:1020-1027. [PMID: 35399022 DOI: 10.3760/cma.j.cn112137-20210814-01816] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the clinical manifestations, imaging, pathological and molecular features of bronchopulmonary large-cell neuroendocrine carcinoma (LCNEC). Methods: The clinical data of 216 LCNEC patients in the First Affiliated Hospital of Zhengzhou University from 2011 to 2021 were analyzed retrospectively. The clinical manifestations, tumor location and size, characteristics of CT images, immunohistochemical and molecular pathological features were analyzed and compared with 115 cases of mixed small cell carcinoma (M-SCLC) diagnosed in the same period. Results: Among the 216 LCNEC patients, there were 190 males and 26 females, with a median age of 65 years. The first symptoms of the patients were mainly cough (106 cases, 49.1%) and bloody sputum (48 cases, 22.2%). The median tumor length were 4.7cm, including 55 cases of nodular type (25.5%) and 161 cases of mass-forming type (74.5%). CT imaging results showed that LCNEC lesions had soft tissue density, and the proportion of slight enhancement lesions was significantly lower than that in M-SCLC group (52.3% vs 74.8%, P<0.001). In contrast, the proportion of necrosis (87.0% vs 58.3%, P<0.001) and calcification (26.9% vs 2.6%, P<0.001) in LCNEC patients was significantly higher than that in M-SCLC group. Immunohistochemical results showed that the positive rate of CK in LCNEC was significantly higher than that in M-SCLC (99.0 % vs 90.5%, P<0.05), while the positive rate of TTF-1 was significantly lower than that in M-SCLC (51.6% vs 67.0%, P<0.05). In LCNEC group, the proportion of patients with Ki-67 positive index between 50% and 80% was significantly higher than that of M-SCLC (41.2% vs 25.2%), while the proportion between 80% and 100% was lower than that of M-SCLC (51.9% vs 72.2%). There was no significant difference in the positive rates of CD56 (91.7% vs 94.6%, P=0.336), Syn (83.8% vs 84.7%, P=0.838) and CgA (54.8% vs 50.0%, P=0.632) in both tumor types. Molecular pathology results showed that frequent mutatios were TP53 (54.5%), RB1 (36.4%), KEAP1 (18.2%), MYC(18.2%), and PTEN (14.3%), and the rate of tumor mutation burden which is more than 25 mutation/Mb was 27.3%. Conclusions: LCNEC lacks specific clinical manifestations. CT imaging is powerful in distinguishing LCNEC from M-SCLC. LCNEC contains a specific mutation spectrum. Pathology combined with immunohistochemical staining is still the gold standard for LCNEC diagnosis, and the differentiation from M-SCLC mainly depends on cell size and nuclear chromatin pattern with light microscopy.
Collapse
Affiliation(s)
- Y Meng
- Department of Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - Y B Lian
- Imaging and Nuclear Ward, Department of Radiology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - Y Xu
- Department of Pathology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - J Q Dong
- Imaging and Nuclear Ward, Department of Radiology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - M Song
- Department of Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| |
Collapse
|
28
|
Kesseli S, Krischak M, Gao Q, Halpern S, Zhang M, Song M, Gonzalez T, Asokan A, Barbas A, Hartwig M. Intra-Tracheal Adeno-Associated Virus Mediates Gene Transduction During Static Cold Storage in Rodent Lung Transplantation. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.087] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
29
|
Song M, Shi H. Independent association of serum serine levels and risk of cancer: a prospective case-control study nested in china stroke primary prevention trial. Clin Nutr ESPEN 2021. [DOI: 10.1016/j.clnesp.2021.09.464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Luo Q, Hofmann J, Song M, Pfeiffer R, Shiels M. Impact of overweight and obesity on U.S. renal cell carcinoma rates. Ann Epidemiol 2021. [DOI: 10.1016/j.annepidem.2021.05.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
31
|
Li Z, Zhou Y, Tian G, Song M. Identification of Core Genes and Key Pathways in Gastric Cancer using Bioinformatics Analysis. RUSS J GENET+ 2021. [DOI: 10.1134/s1022795421080081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
32
|
Zhang X, Li MH, Chen SW, Yang ZY, Li QL, Yang AK, Zhang Q, Song M. [Transoral robotic surgery for parapharyngeal space neoplasm: a report of 7 cases]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2021; 56:730-735. [PMID: 34344100 DOI: 10.3760/cma.j.cn115330-20201101-00846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To evaluate the safety, efficacy and feasibility of transoral robotic surgery (TORS) for parapharyngeal space (PPS) neoplasms. Methods: We collected data from 7 patients with PPS neoplasm who received TORS in Sun Yat-sen University Cancer Center between May 2017 and November 2020, and patients' clinical and pathological characteristics were analysed. There were 2 men and 5 women with age ranged from 35 to 76 years. Among them, 2 patients underwent secondary surgery, 2 patients required combined transcervical approach to complete surgery, and 1 patient was suspected of ipsilateral cervical lymph node metastasis and scheduled for diagnostic TORS. The preoperative tumor size, operation time, intraoperative blood loss, postoperative bleeding, dyspnea, neurological impairment, feeding time and postoperative hospital stay were analyzed. SPSS 24.0 was used to analyze the data. Results: TORS was performed successfully with complete removal of tumors in all 7 cases. Among 6 patients with curative TORS, 5 patients received TORS with postoperative diagnoses of neurogenic tumors and 1 patient underwent TORS combined transcervical approach with postoperative disgnosis of recurrent pleomorphic adenoma; no intraoperative tumor rupture occurred; the intraoperative blood loss was 20-200 ml with a median of 40 ml; the operation time was 65.0-238.0 min with a median of 77.5 min; the oral feeding time was 3-6 days with a median of 3 days; and the postoperative hospital stay was 4.2±1.6 days. One patient presented with neck swelling 3 days after surgery, but this symptom relieved 3 days later after treatments with antibiotic, hemostasis and detumescence. One patient received diagnostic TORS, as intraoperative pathology indicating a recurrent pleomorphic adenoma, then the neoplasm got completely resected through transcervical-transparotid approach. None of 7 patients manifested with airway obstruction, bleeding or nerve injury symptoms after operation. All patients were followed for 2 to 44 months, no local recurrence or distant metastasis was found. Conclusions: TORS is a safe, effective and feasible treatment for selected PPS neoplasms, with less cosmetic impact, less trauma and blood loss, few postoperative complications, enhanced postoperative recovery and short hospital stay.
Collapse
Affiliation(s)
- X Zhang
- Department of Head and Neck Surgery, Sun Yat - sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
| | - M H Li
- Department of Head and Neck Surgery, Sun Yat - sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
| | - S W Chen
- Department of Head and Neck Surgery, Sun Yat - sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
| | - Z Y Yang
- Department of Head and Neck Surgery, Sun Yat - sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
| | - Q L Li
- Department of Head and Neck Surgery, Sun Yat - sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
| | - A K Yang
- Department of Head and Neck Surgery, Sun Yat - sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
| | - Q Zhang
- Department of Head and Neck Surgery, Sun Yat - sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
| | - M Song
- Department of Head and Neck Surgery, Sun Yat - sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
| |
Collapse
|
33
|
Griffiths CEM, Papp K, Song M, Miller M, You Y, Shen YK, Blauvelt A. AB0532 MAINTENANCE OF RESPONSE THROUGH 5 YEARS OF CONTINUOUS GUSELKUMAB TREATMENT: RESULTS FROM THE PHASE-3 VOYAGE 1 TRIAL. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.960] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:VOYAGE 1, a phase-3, double-blinded, placebo- and active comparator-controlled study evaluated the efficacy and safety of guselkumab (GUS; a fully human anti-interleukin-23 monoclonal antibody) in patients with moderate-to-severe plaque psoriasis.1,2,3Objectives:To assess the efficacy and safety through 5 years of continuous GUS treatment.Methods:In VOYAGE 1, patients were randomized to GUS 100 mg at Weeks 0, 4, 12, then every 8 weeks (q8w); placebo at Weeks 0, 4, 12 followed by GUS 100 mg at Weeks 16, 20 then q8w; or adalimumab 80 mg at Week 0, 40 mg at Week 1, then 40 mg every 2 weeks (q2w) through Week 47. At Week 52, all patients continued open-label GUS through Week 252. Efficacy assessments included proportions of patients achieving ≥90% or 100% improvement in Psoriasis Area and Severity Index (PASI 90, PASI 100), and Investigator’s Global Assessment scores of cleared/minimal or cleared (IGA 0/1, IGA 0). Three statistical methods were used to analyze efficacy: prespecified Treatment Failure Rules (TFR), Nonresponder Imputation (NRI), and As Observed (OBS). For TFR analyses, patients who discontinued study agent due to lack of efficacy, worsening of psoriasis, or use of a protocol-prohibited psoriasis treatment were considered nonresponders. For NRI analyses, patients with missing efficacy data (regardless of the reason) after application of TFR were counted as nonresponders. For OBS analyses, missing data were not imputed. Safety was assessed through Week 264.Results:Among a total of 494 patients randomized to GUS at Week 0 (N=329) and placebo patients who crossed over to GUS at Week 16 (N=165), 76.9% (380/494) continued study agent through Week 252. PASI 90 responses were well-maintained with up to 5 years of continuous GUS use. At Week 52, PASI 90 response rates were 79.7%, 75.5%, and 80.6% based on TFR, NRI, and OBS analyses, respectively; corresponding rates at Week 252 were 84.1%, 66.6%, and 86.6%. Likewise, PASI 100, IGA 0/1, and IGA 0 responses were maintained from Week 52 through Week 252 (Table 1). Efficacy was also maintained through Week 252 in patients randomized to GUS at Week 0 (N=329). Through the end of the study for all patients (GUS group and adalimumab→GUS crossover group; N=774), the proportion of patients reporting at least one adverse event (AE), serious AE, or discontinuation due to AEs were 87.7%, 16.4%, and 6.1%, respectively. Rates of AEs of interest through Week 264 were as follows: serious infections (2.8%), malignancies (nonmelanoma skin cancer [1.7%]; cancer other than nonmelanoma skin cancer [2.3%]), major adverse cardiovascular events (1.0%), and suicidal ideation and behavior (0.6%).Conclusion:High efficacy response rates were maintained (regardless of the method used to analyze data) and no new safety concerns were identified through 5 years of continuous GUS treatment in VOYAGE 1.References:[1]Blauvelt A et al. J Am Acad Derm 2017;76:405-417[2]Griffiths CEM et al. J Drugs Dermatol 2018;17:826-832[3]Griffiths CEM et al. J Dermatol Treat 2020;13:1-9Table 1.Proportion of Patients in the GUS Groupa Achieving Clinical Responses by Analysis Type at Week 52 and Week 252Week 52Week 252TFR (N=468)(%)NRI (N=494)(%)OBS (N=463)(%)TFR (N=391)(%)NRI (N=494)(%)OBS (N=380)(%) PASI 90 77.9 75.5 80.6 84.1 66.686.6 PASI 100 49.7 46.6 49.7 52.741.7 54.2 IGA 0 84.6 80.2 85.582.4 65.2 84.7IGA 0 53.3 50.854.254.743.356.3GUS, guselkumab; IGA, Investigator’s Global Assessment; NRI, nonresponder imputation method; OBS, As Observed method; PASI, Psoriasis Area and Severity Index; TFR, treatment failure rules methodaIncludes patients randomized to GUS and placebo patients who crossed over to GUS at Week 16Disclosure of Interests:Christopher E.M. Griffiths Speakers bureau: AbbVie, Eli Lilly, Janssen, Leo, Novartis, Pfizer, Sandoz, and Sun Pharma, Consultant of: AbbVie, Eli Lilly, Janssen, Leo, Novartis, Pfizer, Sandoz, and Sun Pharma, Grant/research support from: AbbVie, Eli Lilly, Janssen, Leo, Novartis, Pfizer, Sandoz, and Sun Pharma, Kim Papp Speakers bureau: AbbVie, Amgen, Astellas, Baxalta, Baxter, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Centocor, Dermira, Eli Lilly, Forward Pharma, Galderma, Genentech, GlaxoSmithKline, Janssen, Kyowa-Hakko Kirin, Leo Pharma, MedImmune, Merck-Serono, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Roche, Sanofi-Genzyme, Stiefel, Sun Pharma, Takeda, UCB, and Valeant, Consultant of: AbbVie, Amgen, Astellas, Baxalta, Baxter, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Centocor, Dermira, Eli Lilly, Forward Pharma, Galderma, Genentech, GlaxoSmithKline, Janssen, Kyowa-Hakko Kirin, Leo Pharma, MedImmune, Merck-Serono, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Roche, Sanofi-Genzyme, Stiefel, Sun Pharma, Takeda, UCB, and Valeant, Grant/research support from: AbbVie, Amgen, Astellas, Baxalta, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Centocor, Dermira, Eli Lilly, Galderma, Genentech, GlaxoSmithKline, Janssen, Kyowa-Hakko Kirin, Leo Pharma, MedImmune, Merck-Serono, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Roche, Sanofi-Genzyme, Stiefel, Takeda, UCB, and Valeant, Michael Song Shareholder of: Johnson and Johnson, Employee of: Janssen Research & Development, LLC, Megan Miller Shareholder of: Johnson and Johnson, Employee of: Janssen Research & Development, LLC, Yin You Shareholder of: Johnson and Johnson, Employee of: Janssen Research & Development, LLC, Yaung-Kaung Shen Shareholder of: Johnson and Johnson, Employee of: Janssen Research & Development, LLC, Andrew Blauvelt Speakers bureau: AbbVie, Consultant of: AbbVie, Aclaris, Almirall, Arena, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Dermira, Eli Lilly, FLX Bio, Forte, Galderma, Janssen, Leo, Novartis, Ortho, Pfizer, Regeneron, Sandoz, Sanofi Genzyme, Sun Pharma, and UCB Pharma.
Collapse
|
34
|
Zhang M, Wang R, Tian J, Song M, Zhao R, Liu K, Zhu F, Shim JH, Dong Z, Lee MH. Targeting LIMK1 with luteolin inhibits the growth of lung cancer in vitro and in vivo. J Cell Mol Med 2021; 25:5560-5571. [PMID: 33982869 PMCID: PMC8184676 DOI: 10.1111/jcmm.16568] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2020] [Revised: 03/02/2021] [Accepted: 04/10/2021] [Indexed: 12/17/2022] Open
Abstract
Lung cancer is the leading cause of cancer‐related deaths. LIM domain kinase (LIMK) 1 is a member of serine/threonine kinase family and highly expressed in various cancers. Luteolin, a polyphenolic plant flavonoid, has been reported to suppress tumour proliferation through inducing apoptosis and autophagy via MAPK activation in glioma. However, the mechanism of luteolin on suppressing lung cancer growth is still unclear. We found that luteolin targeted LIMK1 from the in silico screening and significantly inhibited the LIMK1 kinase activity, which was confirmed with pull‐down binding assay and computational docking models. Treatment with luteolin inhibited lung cancer cells anchorage‐independent colony growth and induced apoptosis and cell cycle arrest at G1 phase. Luteolin also decreased the expression of cyclin D1 and increased the levels of cleaved caspase‐3 by down‐regulating LIMK1 signalling related targets, including p‐LIMK and p‐cofilin. Furthermore, luteolin suppressed the lung cancer patient‐derived xenograft tumour growth by decreasing Ki‐67, p‐LIMK and p‐cofilin expression in vivo. Taken together, these results provide insight into the mechanism that underlies the anticancer effects of luteolin on lung cancer, which involved in down‐regulation of LIMK1 and its interaction with cofilin. It also provides valuable evidence for translation towards lung cancer clinical trials with luteolin.
Collapse
Affiliation(s)
- Man Zhang
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Rui Wang
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Jie Tian
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Mengqiu Song
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.,Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
| | - Ran Zhao
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.,Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
| | - Kangdong Liu
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.,Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
| | - Feng Zhu
- Cancer Research Institute, The Affiliated Hospital of Guilin Medical University, Guilin, China
| | - Jung-Hyun Shim
- Department of Pharmacy, College of Pharmacy, Mokpo National University, Muan, Republic of Korea
| | - Zigang Dong
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.,Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
| | - Mee-Hyun Lee
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.,Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.,College of Korean Medicine, Dongshin University, Naju, Republic of Korea
| |
Collapse
|
35
|
Yue Y, Hur J, Cao Y, Tabung FK, Wang M, Wu K, Song M, Zhang X, Liu Y, Meyerhardt JA, Ng K, Smith-Warner SA, Willett WC, Giovannucci E. Prospective evaluation of dietary and lifestyle pattern indices with risk of colorectal cancer in a cohort of younger women. Ann Oncol 2021; 32:778-786. [PMID: 33812017 DOI: 10.1016/j.annonc.2021.03.200] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2021] [Revised: 03/22/2021] [Accepted: 03/23/2021] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Although colorectal cancer (CRC) incidence in the USA is declining overall, its incidence is increasing among those younger than 50 years of age. The reasons underlying the increasing trend are largely unknown, although behavioral changes, such as unhealthy diet and lifestyle factors, may be partially responsible. DESIGN A prospective cohort study included 94 217 women aged 26-45 years at baseline. Validated anthropometric measures and lifestyle information were self-reported biennially. Exposures were four recommendation-based dietary indices-the prime diet quality score and three plant-based dietary indices; and two mechanism-based indices-the empirical dietary and lifestyle index for hyperinsulinemia (EDIH and ELIH). We calculated hazard ratios (HRs) and 95% confidence intervals (CIs) for overall CRC and for early-onset (before age 50) and after age 50 CRC separately. RESULTS We documented 332 cases of CRC during 24 years of follow-up (2 113 655 person-years), with an average age of 52 ± 7 years at diagnosis. Hyperinsulinemic dietary and lifestyle patterns were associated with a higher risk of CRC. Multivariable-adjusted HRs (95% CIs) comparing participants in the highest versus lowest quartile were: 1.67 for EDIH (95% CI: 1.15-2.44, P-trend = 0.01) and 1.51 for ELIH (95% CI: 1.10-2.08, P-trend = 0.01). Moreover, per 75% increment in rank, ELIH appeared to be a stronger risk factor for early-onset CRC (HR = 1.86, 95% CI: 1.12-3.07) than after age 50 CRC (HR = 1.20, 95% CI: 0.83-1.73, P-heterogeneity = 0.16). The four recommendation-based indices were not significantly associated with overall, early-onset, or after age 50 CRC risk (per 75% increment in rank, HRs ranged from 0.75 to 1.28). CONCLUSION Dietary and lifestyle patterns contributing to hyperinsulinemia were associated with greater CRC risk in younger women. Moreover, the hyperinsulinemic lifestyle showed a suggestively stronger positive association with early-onset CRC risk, compared with after age 50 CRC. Our findings suggest that dietary and lifestyle interventions to reduce insulinemic potential may be effective for CRC prevention among younger women.
Collapse
Affiliation(s)
- Y Yue
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, USA
| | - J Hur
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, USA.
| | - Y Cao
- Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, USA; Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, USA; Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, USA
| | - F K Tabung
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, USA; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, USA; The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, USA
| | - M Wang
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA
| | - K Wu
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, USA
| | - M Song
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA; Harvard Medical School, Boston, USA
| | - X Zhang
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA
| | - Y Liu
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA; Clinical and Translational Epidemiology Unit and Division of Gastroenterology, Massachusetts General Hospital, Boston, USA
| | - J A Meyerhardt
- Evidence-Based Chinese Medicine, School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, P.R. China
| | - K Ng
- Evidence-Based Chinese Medicine, School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, P.R. China
| | - S A Smith-Warner
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, USA
| | - W C Willett
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA
| | - E Giovannucci
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA.
| |
Collapse
|
36
|
Zhou H, Zhang Y, Zhao Y, Ji L, Song M, Li P, Guan Y, Xia X, Zhou N. FP10.03 Multi-Region Exome Sequencing Reveals the Intratumoral Heterogeneity of Surgically Resected Small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
37
|
Gu T, Zhao S, Jin G, Song M, Zhi Y, Zhao R, Ma F, Zheng Y, Wang K, Liu H, Xin M, Han W, Li X, Dong CD, Liu K, Dong Z. Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model. Front Immunol 2021; 11:621441. [PMID: 33584719 PMCID: PMC7876321 DOI: 10.3389/fimmu.2020.621441] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Accepted: 12/29/2020] [Indexed: 12/15/2022] Open
Abstract
Although COVID-19 has become a major challenge to global health, there are currently no efficacious agents for effective treatment. Cytokine storm syndrome (CSS) can lead to acute respiratory distress syndrome (ARDS), which contributes to most COVID-19 mortalities. Research points to interleukin 6 (IL-6) as a crucial signature of the cytokine storm, and the clinical use of the IL-6 inhibitor tocilizumab shows potential for treatment of COVID-19 patient. In this study, we challenged wild-type and adenovirus-5/human angiotensin-converting enzyme 2-expressing BALB/c mice with a combination of polyinosinic-polycytidylic acid and recombinant SARS-CoV-2 spike-extracellular domain protein. High levels of TNF-α and nearly 100 times increased IL-6 were detected at 6 h, but disappeared by 24 h in bronchoalveolar lavage fluid (BALF) following immunostimulant challenge. Lung injury observed by histopathologic changes and magnetic resonance imaging at 24 h indicated that increased TNF-α and IL-6 may initiate CSS in the lung, resulting in the continual production of inflammatory cytokines. We hypothesize that TNF-α and IL-6 may contribute to the occurrence of CSS in COVID-19. We also investigated multiple monoclonal antibodies (mAbs) and inhibitors for neutralizing the pro-inflammatory phenotype of COVID-19: mAbs against IL-1α, IL-6, TNF-α, and granulocyte-macrophage colony-stimulating factor (GM-CSF), and inhibitors of p38 and JAK partially relieved CSS; mAbs against IL-6, TNF-α, and GM-CSF, and inhibitors of p38, extracellular signal-regulated kinase, and myeloperoxidase somewhat reduced neutrophilic alveolitis in the lung. This novel murine model opens a biologically safe, time-saving avenue for clarifying the mechanism of CSS/ARDS in COVID-19 and developing new therapeutic drugs.
Collapse
Affiliation(s)
- Tingxuan Gu
- Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, China.,China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Simin Zhao
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.,Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
| | - Guoguo Jin
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.,The Henan Luoyang Orthopedic Hospital, Zhengzhou, China
| | - Mengqiu Song
- Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, China.,China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Yafei Zhi
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Ran Zhao
- Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, China.,China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Fayang Ma
- Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, China.,China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Yaqiu Zheng
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Keke Wang
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Hui Liu
- Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, China.,China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Mingxia Xin
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Wei Han
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Xiang Li
- Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, China.,China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.,Henan Provincial Cooperative Innovation Center for Cancer Chemoprevention, Zhengzhou University, Zhengzhou, China
| | | | - Kangdong Liu
- Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, China.,China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.,Henan Provincial Cooperative Innovation Center for Cancer Chemoprevention, Zhengzhou University, Zhengzhou, China
| | - Zigang Dong
- Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, China.,China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| |
Collapse
|
38
|
Zhang M, Tian J, Wang R, Song M, Zhao R, Chen H, Liu K, Shim JH, Zhu F, Dong Z, Lee MH. Dasatinib Inhibits Lung Cancer Cell Growth and Patient Derived Tumor Growth in Mice by Targeting LIMK1. Front Cell Dev Biol 2020; 8:556532. [PMID: 33344441 PMCID: PMC7746816 DOI: 10.3389/fcell.2020.556532] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2020] [Accepted: 10/26/2020] [Indexed: 12/18/2022] Open
Abstract
Lung cancer is a leading cause cancer-related death with diversity. A promising approach to meet the need for improved cancer treatment is drug repurposing. Dasatinib, a second generation of tyrosine kinase inhibitors (TKIs), is a potent treatment agent for chronic myeloid leukemia (CML) approved by FDA, however, its off-targets and the underlying mechanisms in lung cancer have not been elucidated yet. LIM kinase 1 (LIMK1) is a serine/threonine kinase, which is highly upregulated in human cancers. Herein, we demonstrated that dasatinib dose-dependently blocked lung cancer cell proliferation and repressed LIMK1 activities by directly targeting LIMK1. It was confirmed that knockdown of LIMK1 expression suppressed lung cancer cell proliferation. From the in silico screening results, dasatinib may target to LIMK1. Indeed, dasatinib significantly inhibited the LIMK1 activity as evidenced by kinase and binding assay, and computational docking model analysis. Dasatinib inhibited lung cancer cell growth, while induced cell apoptosis as well as cell cycle arrest at the G1 phase. Meanwhile, dasatinib also suppressed the expression of markers relating cell cycle, cyclin D1, D3, and CDK2, and increased the levels of markers involved in cell apoptosis, cleaved caspase-3 and caspase-7 by downregulating phosphorylated LIMK1 (p-LIMK1) and cofilin (p-cofilin). Furthermore, in patient-derived xenografts (PDXs), dasatinib (30 mg/kg) significantly inhibited the growth of tumors in SCID mice which highly expressed LIMK1 without changing the bodyweight. In summary, our results indicate that dasatinib acts as a novel LIMK1 inhibitor to suppress the lung cancer cell proliferation in vitro and tumor growth in vivo, which suggests evidence for the application of dasatinib in lung cancer therapy.
Collapse
Affiliation(s)
- Man Zhang
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Jie Tian
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Rui Wang
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Mengqiu Song
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.,Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
| | - Ran Zhao
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.,Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
| | - Hanyong Chen
- The Hormel Institute, University of Minnesota, Minneapolis, MN, United States
| | - Kangdong Liu
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.,Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
| | - Jung-Hyun Shim
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.,Department of Pharmacy, College of Pharmacy, Mokpo National University, Jeonnam, South Korea
| | - Feng Zhu
- Cancer Research Institute, The Affiliated Hospital of Guilin Medical University, Guilin, China
| | - Zigang Dong
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.,Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
| | - Mee-Hyun Lee
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.,Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.,College of Korean Medicine, Dongshin University, Naju, South Korea
| |
Collapse
|
39
|
Song M, Zhang Q, Xu H, Li W, Shi H, Song C. Development of nomograms predicting overall survival of breast cancer based on indicators of nutritional status: An observational prospective study. Clin Nutr ESPEN 2020. [DOI: 10.1016/j.clnesp.2020.09.267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
40
|
Aartsen MG, Abbasi R, Ackermann M, Adams J, Aguilar JA, Ahlers M, Ahrens M, Alispach C, Amin NM, Andeen K, Anderson T, Ansseau I, Anton G, Argüelles C, Auffenberg J, Axani S, Bagherpour H, Bai X, Balagopal A, Barbano A, Barwick SW, Bastian B, Basu V, Baum V, Baur S, Bay R, Beatty JJ, Becker KH, Becker Tjus J, BenZvi S, Berley D, Bernardini E, Besson DZ, Binder G, Bindig D, Blaufuss E, Blot S, Bohm C, Böser S, Botner O, Böttcher J, Bourbeau E, Bourbeau J, Bradascio F, Braun J, Bron S, Brostean-Kaiser J, Burgman A, Buscher J, Busse RS, Carver T, Chen C, Cheung E, Chirkin D, Choi S, Clark BA, Clark K, Classen L, Coleman A, Collin GH, Conrad JM, Coppin P, Correa P, Cowen DF, Cross R, Dave P, De Clercq C, DeLaunay JJ, Dembinski H, Deoskar K, De Ridder S, Desai A, Desiati P, de Vries KD, de Wasseige G, de With M, DeYoung T, Dharani S, Diaz A, Díaz-Vélez JC, Dujmovic H, Dunkman M, DuVernois MA, Dvorak E, Ehrhardt T, Eller P, Engel R, Evenson PA, Fahey S, Fazely AR, Fedynitch A, Felde J, Fienberg AT, Filimonov K, Finley C, Fox D, Franckowiak A, Friedman E, Fritz A, Gaisser TK, Gallagher J, Ganster E, Garrappa S, Gerhardt L, Glauch T, Glüsenkamp T, Goldschmidt A, Gonzalez JG, Grant D, Grégoire T, Griffith Z, Griswold S, Günder M, Gündüz M, Haack C, Hallgren A, Halliday R, Halve L, Halzen F, Hanson K, Hardin J, Haungs A, Hauser S, Hebecker D, Heereman D, Heix P, Helbing K, Hellauer R, Henningsen F, Hickford S, Hignight J, Hill GC, Hoffman KD, Hoffmann R, Hoinka T, Hokanson-Fasig B, Hoshina K, Huang F, Huber M, Huber T, Hultqvist K, Hünnefeld M, Hussain R, In S, Iovine N, Ishihara A, Jansson M, Japaridze GS, Jeong M, Jones BJP, Jonske F, Joppe R, Kang D, Kang W, Kappes A, Kappesser D, Karg T, Karl M, Karle A, Katz U, Kauer M, Kellermann M, Kelley JL, Kheirandish A, Kim J, Kintscher T, Kiryluk J, Kittler T, Klein SR, Koirala R, Kolanoski H, Köpke L, Kopper C, Kopper S, Koskinen DJ, Koundal P, Kowalski M, Krings K, Krückl G, Kulacz N, Kurahashi N, Kyriacou A, Lanfranchi JL, Larson MJ, Lauber F, Lazar JP, Leonard K, Leszczyńska A, Li Y, Liu QR, Lohfink E, Lozano Mariscal CJ, Lu L, Lucarelli F, Ludwig A, Lünemann J, Luszczak W, Lyu Y, Ma WY, Madsen J, Maggi G, Mahn KBM, Makino Y, Mallik P, Mancina S, Mariş IC, Maruyama R, Mase K, Maunu R, McNally F, Meagher K, Medici M, Medina A, Meier M, Meighen-Berger S, Merz J, Meures T, Micallef J, Mockler D, Momenté G, Montaruli T, Moore RW, Morse R, Moulai M, Muth P, Nagai R, Naumann U, Neer G, Nguyen LV, Niederhausen H, Nisa MU, Nowicki SC, Nygren DR, Obertacke Pollmann A, Oehler M, Olivas A, O'Murchadha A, O'Sullivan E, Palczewski T, Pandya H, Pankova DV, Park N, Parker GK, Paudel EN, Peiffer P, Pérez de Los Heros C, Philippen S, Pieloth D, Pieper S, Pinat E, Pizzuto A, Plum M, Popovych Y, Porcelli A, Prado Rodriguez M, Price PB, Przybylski GT, Raab C, Raissi A, Rameez M, Rauch L, Rawlins K, Rea IC, Rehman A, Reimann R, Relethford B, Renschler M, Renzi G, Resconi E, Rhode W, Richman M, Riedel B, Robertson S, Rongen M, Rott C, Ruhe T, Ryckbosch D, Rysewyk Cantu D, Safa I, Sanchez Herrera SE, Sandrock A, Sandroos J, Santander M, Sarkar S, Sarkar S, Satalecka K, Scharf M, Schaufel M, Schieler H, Schlunder P, Schmidt T, Schneider A, Schneider J, Schröder FG, Schumacher L, Sclafani S, Seckel D, Seunarine S, Shefali S, Silva M, Smithers B, Snihur R, Soedingrekso J, Soldin D, Song M, Spiczak GM, Spiering C, Stachurska J, Stamatikos M, Stanev T, Stein R, Stettner J, Steuer A, Stezelberger T, Stokstad RG, Stößl A, Strotjohann NL, Stürwald T, Stuttard T, Sullivan GW, Taboada I, Tenholt F, Ter-Antonyan S, Terliuk A, Tilav S, Tollefson K, Tomankova L, Tönnis C, Toscano S, Tosi D, Trettin A, Tselengidou M, Tung CF, Turcati A, Turcotte R, Turley CF, Ty B, Unger E, Unland Elorrieta MA, Usner M, Vandenbroucke J, Van Driessche W, van Eijk D, van Eijndhoven N, Vannerom D, van Santen J, Verpoest S, Vraeghe M, Walck C, Wallace A, Wallraff M, Watson TB, Weaver C, Weindl A, Weiss MJ, Weldert J, Wendt C, Werthebach J, Whelan BJ, Whitehorn N, Wiebe K, Wiebusch CH, Williams DR, Wills L, Wolf M, Wood TR, Woschnagg K, Wrede G, Wulff J, Xu XW, Xu Y, Yanez JP, Yodh G, Yoshida S, Yuan T, Zhang Z, Zöcklein M. eV-Scale Sterile Neutrino Search Using Eight Years of Atmospheric Muon Neutrino Data from the IceCube Neutrino Observatory. Phys Rev Lett 2020; 125:141801. [PMID: 33064514 DOI: 10.1103/physrevlett.125.141801] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/08/2020] [Accepted: 08/31/2020] [Indexed: 06/11/2023]
Abstract
The results of a 3+1 sterile neutrino search using eight years of data from the IceCube Neutrino Observatory are presented. A total of 305 735 muon neutrino events are analyzed in reconstructed energy-zenith space to test for signatures of a matter-enhanced oscillation that would occur given a sterile neutrino state with a mass-squared differences between 0.01 and 100 eV^{2}. The best-fit point is found to be at sin^{2}(2θ_{24})=0.10 and Δm_{41}^{2}=4.5 eV^{2}, which is consistent with the no sterile neutrino hypothesis with a p value of 8.0%.
Collapse
Affiliation(s)
- M G Aartsen
- Department of Physics and Astronomy, University of Canterbury, Private Bag 4800, Christchurch, New Zealand
| | - R Abbasi
- Department of Physics, Loyola University Chicago, Chicago, Illinois 60660, USA
| | | | - J Adams
- Department of Physics and Astronomy, University of Canterbury, Private Bag 4800, Christchurch, New Zealand
| | - J A Aguilar
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - M Ahlers
- Niels Bohr Institute, University of Copenhagen, DK-2100 Copenhagen, Denmark
| | - M Ahrens
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - C Alispach
- Département de physique nucléaire et corpusculaire, Université de Genève, CH-1211 Genève, Switzerland
| | - N M Amin
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - K Andeen
- Department of Physics, Marquette University, Milwaukee, Wisconsin 53201, USA
| | - T Anderson
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - I Ansseau
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - G Anton
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - C Argüelles
- Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - J Auffenberg
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - S Axani
- Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - H Bagherpour
- Department of Physics and Astronomy, University of Canterbury, Private Bag 4800, Christchurch, New Zealand
| | - X Bai
- Physics Department, South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - A Balagopal
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - A Barbano
- Département de physique nucléaire et corpusculaire, Université de Genève, CH-1211 Genève, Switzerland
| | - S W Barwick
- Department of Physics and Astronomy, University of California, Irvine, California 92697, USA
| | | | - V Basu
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - V Baum
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - S Baur
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - R Bay
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - J J Beatty
- Department of Astronomy, Ohio State University, Columbus, Ohio 43210, USA
- Department of Physics and Center for Cosmology and Astro-Particle Physics, Ohio State University, Columbus, Ohio 43210, USA
| | - K-H Becker
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - J Becker Tjus
- Fakultät für Physik & Astronomie, Ruhr-Universität Bochum, D-44780 Bochum, Germany
| | - S BenZvi
- Department of Physics and Astronomy, University of Rochester, Rochester, New York 14627, USA
| | - D Berley
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | | | - D Z Besson
- Department of Physics and Astronomy, University of Kansas, Lawrence, Kansas 66045, USA
| | - G Binder
- Department of Physics, University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - D Bindig
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - E Blaufuss
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - S Blot
- DESY, D-15738 Zeuthen, Germany
| | - C Bohm
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - S Böser
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - O Botner
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - J Böttcher
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - E Bourbeau
- Niels Bohr Institute, University of Copenhagen, DK-2100 Copenhagen, Denmark
| | - J Bourbeau
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | | | - J Braun
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S Bron
- Département de physique nucléaire et corpusculaire, Université de Genève, CH-1211 Genève, Switzerland
| | | | - A Burgman
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - J Buscher
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - R S Busse
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, D-48149 Münster, Germany
| | - T Carver
- Département de physique nucléaire et corpusculaire, Université de Genève, CH-1211 Genève, Switzerland
| | - C Chen
- School of Physics and Center for Relativistic Astrophysics, Georgia Institute of Technology, Atlanta, Georgia 30332, USA
| | - E Cheung
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - D Chirkin
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S Choi
- Department of Physics, Sungkyunkwan University, Suwon 16419, Korea
| | - B A Clark
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - K Clark
- SNOLAB, 1039 Regional Road 24, Creighton Mine 9, Lively, Ontario P3Y 1N2, Canada
| | - L Classen
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, D-48149 Münster, Germany
| | - A Coleman
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - G H Collin
- Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - J M Conrad
- Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - P Coppin
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | - P Correa
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | - D F Cowen
- Department of Astronomy and Astrophysics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - R Cross
- Department of Physics and Astronomy, University of Rochester, Rochester, New York 14627, USA
| | - P Dave
- School of Physics and Center for Relativistic Astrophysics, Georgia Institute of Technology, Atlanta, Georgia 30332, USA
| | - C De Clercq
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | - J J DeLaunay
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - H Dembinski
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - K Deoskar
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - S De Ridder
- Department of Physics and Astronomy, University of Gent, B-9000 Gent, Belgium
| | - A Desai
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - P Desiati
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - K D de Vries
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | - G de Wasseige
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | - M de With
- Institut für Physik, Humboldt-Universität zu Berlin, D-12489 Berlin, Germany
| | - T DeYoung
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - S Dharani
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - A Diaz
- Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - J C Díaz-Vélez
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - H Dujmovic
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - M Dunkman
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - M A DuVernois
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - E Dvorak
- Physics Department, South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - T Ehrhardt
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - P Eller
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - R Engel
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - P A Evenson
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - S Fahey
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - A R Fazely
- Department of Physics, Southern University, Baton Rouge, Lousiana 70813, USA
| | - A Fedynitch
- Institute for Cosmic Ray Research, the University of Tokyo, 5-1-5 Kashiwa-no-ha, Kashiwa, Chiba 277-8582, Japan
| | - J Felde
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - A T Fienberg
- Department of Astronomy and Astrophysics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - K Filimonov
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - C Finley
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - D Fox
- Department of Astronomy and Astrophysics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | | | - E Friedman
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - A Fritz
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - T K Gaisser
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - J Gallagher
- Department of Astronomy, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - E Ganster
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | | | - L Gerhardt
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - T Glauch
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - T Glüsenkamp
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - A Goldschmidt
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - J G Gonzalez
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - D Grant
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - T Grégoire
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - Z Griffith
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S Griswold
- Department of Physics and Astronomy, University of Rochester, Rochester, New York 14627, USA
| | - M Günder
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - M Gündüz
- Fakultät für Physik & Astronomie, Ruhr-Universität Bochum, D-44780 Bochum, Germany
| | - C Haack
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - A Hallgren
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - R Halliday
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - L Halve
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - F Halzen
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - K Hanson
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - J Hardin
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - A Haungs
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - S Hauser
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - D Hebecker
- Institut für Physik, Humboldt-Universität zu Berlin, D-12489 Berlin, Germany
| | - D Heereman
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - P Heix
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - K Helbing
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - R Hellauer
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - F Henningsen
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - S Hickford
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - J Hignight
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2E1, Canada
| | - G C Hill
- Department of Physics, University of Adelaide, Adelaide 5005, Australia
| | - K D Hoffman
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - R Hoffmann
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - T Hoinka
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - B Hokanson-Fasig
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - K Hoshina
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - F Huang
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - M Huber
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - T Huber
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
- DESY, D-15738 Zeuthen, Germany
| | - K Hultqvist
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - M Hünnefeld
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - R Hussain
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S In
- Department of Physics, Sungkyunkwan University, Suwon 16419, Korea
| | - N Iovine
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - A Ishihara
- Department of Physics and Institute for Global Prominent Research, Chiba University, Chiba 263-8522, Japan
| | - M Jansson
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - G S Japaridze
- CTSPS, Clark-Atlanta University, Atlanta, Georgia 30314, USA
| | - M Jeong
- Department of Physics, Sungkyunkwan University, Suwon 16419, Korea
| | - B J P Jones
- Department of Physics, University of Texas at Arlington, 502 Yates Street, Science Hall Room 108, Box 19059, Arlington, Texas 76019, USA
| | - F Jonske
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - R Joppe
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - D Kang
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - W Kang
- Department of Physics, Sungkyunkwan University, Suwon 16419, Korea
| | - A Kappes
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, D-48149 Münster, Germany
| | - D Kappesser
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - T Karg
- DESY, D-15738 Zeuthen, Germany
| | - M Karl
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - A Karle
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - U Katz
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - M Kauer
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - M Kellermann
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - J L Kelley
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - A Kheirandish
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - J Kim
- Department of Physics, Sungkyunkwan University, Suwon 16419, Korea
| | | | - J Kiryluk
- Department of Physics and Astronomy, Stony Brook University, Stony Brook, New York 11794-3800, USA
| | - T Kittler
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - S R Klein
- Department of Physics, University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - R Koirala
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - H Kolanoski
- Institut für Physik, Humboldt-Universität zu Berlin, D-12489 Berlin, Germany
| | - L Köpke
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - C Kopper
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - S Kopper
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - D J Koskinen
- Niels Bohr Institute, University of Copenhagen, DK-2100 Copenhagen, Denmark
| | - P Koundal
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - M Kowalski
- Institut für Physik, Humboldt-Universität zu Berlin, D-12489 Berlin, Germany
- DESY, D-15738 Zeuthen, Germany
| | - K Krings
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - G Krückl
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - N Kulacz
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2E1, Canada
| | - N Kurahashi
- Department of Physics, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, USA
| | - A Kyriacou
- Department of Physics, University of Adelaide, Adelaide 5005, Australia
| | - J L Lanfranchi
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - M J Larson
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - F Lauber
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - J P Lazar
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - K Leonard
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - A Leszczyńska
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - Y Li
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - Q R Liu
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - E Lohfink
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - C J Lozano Mariscal
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, D-48149 Münster, Germany
| | - L Lu
- Department of Physics and Institute for Global Prominent Research, Chiba University, Chiba 263-8522, Japan
| | - F Lucarelli
- Département de physique nucléaire et corpusculaire, Université de Genève, CH-1211 Genève, Switzerland
| | - A Ludwig
- Department of Physics and Astronomy, UCLA, Los Angeles, California 90095, USA
| | - J Lünemann
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | - W Luszczak
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - Y Lyu
- Department of Physics, University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - W Y Ma
- DESY, D-15738 Zeuthen, Germany
| | - J Madsen
- Department of Physics, University of Wisconsin, River Falls, Wisconsin 54022, USA
| | - G Maggi
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | - K B M Mahn
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - Y Makino
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - P Mallik
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - S Mancina
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - I C Mariş
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - R Maruyama
- Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - K Mase
- Department of Physics and Institute for Global Prominent Research, Chiba University, Chiba 263-8522, Japan
| | - R Maunu
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - F McNally
- Department of Physics, Mercer University, Macon, Georgia 31207-0001, USA
| | - K Meagher
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - M Medici
- Niels Bohr Institute, University of Copenhagen, DK-2100 Copenhagen, Denmark
| | - A Medina
- Department of Physics and Center for Cosmology and Astro-Particle Physics, Ohio State University, Columbus, Ohio 43210, USA
| | - M Meier
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - S Meighen-Berger
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - J Merz
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - T Meures
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - J Micallef
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - D Mockler
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - G Momenté
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - T Montaruli
- Département de physique nucléaire et corpusculaire, Université de Genève, CH-1211 Genève, Switzerland
| | - R W Moore
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2E1, Canada
| | - R Morse
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - M Moulai
- Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - P Muth
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - R Nagai
- Department of Physics and Institute for Global Prominent Research, Chiba University, Chiba 263-8522, Japan
| | - U Naumann
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - G Neer
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - L V Nguyen
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - H Niederhausen
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - M U Nisa
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - S C Nowicki
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - D R Nygren
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | | | - M Oehler
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - A Olivas
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - A O'Murchadha
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - E O'Sullivan
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - T Palczewski
- Department of Physics, University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - H Pandya
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - D V Pankova
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - N Park
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - G K Parker
- Department of Physics, University of Texas at Arlington, 502 Yates Street, Science Hall Room 108, Box 19059, Arlington, Texas 76019, USA
| | - E N Paudel
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - P Peiffer
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - C Pérez de Los Heros
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - S Philippen
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - D Pieloth
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - S Pieper
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - E Pinat
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - A Pizzuto
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - M Plum
- Department of Physics, Marquette University, Milwaukee, Wisconsin 53201, USA
| | - Y Popovych
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - A Porcelli
- Department of Physics and Astronomy, University of Gent, B-9000 Gent, Belgium
| | - M Prado Rodriguez
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - P B Price
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - G T Przybylski
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - C Raab
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - A Raissi
- Department of Physics and Astronomy, University of Canterbury, Private Bag 4800, Christchurch, New Zealand
| | - M Rameez
- Niels Bohr Institute, University of Copenhagen, DK-2100 Copenhagen, Denmark
| | - L Rauch
- DESY, D-15738 Zeuthen, Germany
| | - K Rawlins
- Department of Physics and Astronomy, University of Alaska Anchorage, 3211 Providence Drive, Anchorage, Alaska 99508, USA
| | - I C Rea
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - A Rehman
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - R Reimann
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - B Relethford
- Department of Physics, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, USA
| | - M Renschler
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - G Renzi
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - E Resconi
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - W Rhode
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - M Richman
- Department of Physics, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, USA
| | - B Riedel
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S Robertson
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - M Rongen
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - C Rott
- Department of Physics, Sungkyunkwan University, Suwon 16419, Korea
| | - T Ruhe
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - D Ryckbosch
- Department of Physics and Astronomy, University of Gent, B-9000 Gent, Belgium
| | - D Rysewyk Cantu
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - I Safa
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S E Sanchez Herrera
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - A Sandrock
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - J Sandroos
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - M Santander
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - S Sarkar
- Department of Physics, University of Oxford, Parks Road, Oxford OX1 3PU, United Kingdom
| | - S Sarkar
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2E1, Canada
| | | | - M Scharf
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - M Schaufel
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - H Schieler
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - P Schlunder
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - T Schmidt
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - A Schneider
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - J Schneider
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - F G Schröder
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - L Schumacher
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - S Sclafani
- Department of Physics, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, USA
| | - D Seckel
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - S Seunarine
- Department of Physics, University of Wisconsin, River Falls, Wisconsin 54022, USA
| | - S Shefali
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - M Silva
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - B Smithers
- Department of Physics, University of Texas at Arlington, 502 Yates Street, Science Hall Room 108, Box 19059, Arlington, Texas 76019, USA
| | - R Snihur
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - J Soedingrekso
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - D Soldin
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - M Song
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - G M Spiczak
- Department of Physics, University of Wisconsin, River Falls, Wisconsin 54022, USA
| | | | | | - M Stamatikos
- Department of Physics and Center for Cosmology and Astro-Particle Physics, Ohio State University, Columbus, Ohio 43210, USA
| | - T Stanev
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - R Stein
- DESY, D-15738 Zeuthen, Germany
| | - J Stettner
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - A Steuer
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - T Stezelberger
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - R G Stokstad
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A Stößl
- Department of Physics and Institute for Global Prominent Research, Chiba University, Chiba 263-8522, Japan
| | | | - T Stürwald
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - T Stuttard
- Niels Bohr Institute, University of Copenhagen, DK-2100 Copenhagen, Denmark
| | - G W Sullivan
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - I Taboada
- School of Physics and Center for Relativistic Astrophysics, Georgia Institute of Technology, Atlanta, Georgia 30332, USA
| | - F Tenholt
- Fakultät für Physik & Astronomie, Ruhr-Universität Bochum, D-44780 Bochum, Germany
| | - S Ter-Antonyan
- Department of Physics, Southern University, Baton Rouge, Lousiana 70813, USA
| | | | - S Tilav
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - K Tollefson
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - L Tomankova
- Fakultät für Physik & Astronomie, Ruhr-Universität Bochum, D-44780 Bochum, Germany
| | - C Tönnis
- Institute of Basic Science, Sungkyunkwan University, Suwon 16419, Korea
| | - S Toscano
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - D Tosi
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | | | - M Tselengidou
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - C F Tung
- School of Physics and Center for Relativistic Astrophysics, Georgia Institute of Technology, Atlanta, Georgia 30332, USA
| | - A Turcati
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - R Turcotte
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - C F Turley
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - B Ty
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - E Unger
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - M A Unland Elorrieta
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, D-48149 Münster, Germany
| | - M Usner
- DESY, D-15738 Zeuthen, Germany
| | - J Vandenbroucke
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - W Van Driessche
- Department of Physics and Astronomy, University of Gent, B-9000 Gent, Belgium
| | - D van Eijk
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - N van Eijndhoven
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | - D Vannerom
- Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | | | - S Verpoest
- Department of Physics and Astronomy, University of Gent, B-9000 Gent, Belgium
| | - M Vraeghe
- Department of Physics and Astronomy, University of Gent, B-9000 Gent, Belgium
| | - C Walck
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - A Wallace
- Department of Physics, University of Adelaide, Adelaide 5005, Australia
| | - M Wallraff
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - T B Watson
- Department of Physics, University of Texas at Arlington, 502 Yates Street, Science Hall Room 108, Box 19059, Arlington, Texas 76019, USA
| | - C Weaver
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2E1, Canada
| | - A Weindl
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - M J Weiss
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - J Weldert
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - C Wendt
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - J Werthebach
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - B J Whelan
- Department of Physics, University of Adelaide, Adelaide 5005, Australia
| | - N Whitehorn
- Department of Physics and Astronomy, UCLA, Los Angeles, California 90095, USA
| | - K Wiebe
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - C H Wiebusch
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - D R Williams
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - L Wills
- Department of Physics, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, USA
| | - M Wolf
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - T R Wood
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2E1, Canada
| | - K Woschnagg
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - G Wrede
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - J Wulff
- Fakultät für Physik & Astronomie, Ruhr-Universität Bochum, D-44780 Bochum, Germany
| | - X W Xu
- Department of Physics, Southern University, Baton Rouge, Lousiana 70813, USA
| | - Y Xu
- Department of Physics and Astronomy, Stony Brook University, Stony Brook, New York 11794-3800, USA
| | - J P Yanez
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2E1, Canada
| | - G Yodh
- Department of Physics and Astronomy, University of California, Irvine, California 92697, USA
| | - S Yoshida
- Department of Physics and Institute for Global Prominent Research, Chiba University, Chiba 263-8522, Japan
| | - T Yuan
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - Z Zhang
- Department of Physics and Astronomy, Stony Brook University, Stony Brook, New York 11794-3800, USA
| | - M Zöcklein
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| |
Collapse
|
41
|
Tian G, Wang SW, Song M, Hu YF, Cao XN, Ge JW. MicroRNA-16 inhibits the proliferation, migration and invasion of non-small cell lung carcinoma cells by down-regulating matrix metalloproteinase-19 expression. Eur Rev Med Pharmacol Sci 2020; 23:5260-5269. [PMID: 31298377 DOI: 10.26355/eurrev_201906_18192] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE This study aims to investigate the expression of microRNA (miR)-16 in non-small cell lung carcinoma (NSCLC) and to identify its potential mechanism. PATIENTS AND METHODS A total of 45 NSCLC patients were included in the present work. NSCLC tissues and adjacent normal tissues were resected and collected. The Reverse Transcription-quantitative Polymerase Chain Reaction was used to determine miR-16 expression. Regulatory effects of miR-16 on proliferation, migration and invasion, and cell cycle of A549 cells were determined by Cell-Counting Kit 8 assay, transwell assay, and flow cytometry, respectively. Western blotting was performed to measure the protein expression of matrix metalloproteinase (MMP)-19 in cells overexpressing miR-16. Dual-luciferase reporter gene assay was conducted to identify the interaction between miR-16 and MMP-19. RESULTS MiR-16 expression in NSCLC significantly decreased compared with that in healthy tissue (p<0.05). The expression level of miR-16 was negatively correlated to the clinical staging of NSCLC. In addition, the expression of miR-16 in NSCLC patients with lymph node metastasis was significantly lower than that in patients without lymph node metastasis (p<0.05). In vitro studies demonstrated that miR-16 inhibited the proliferation, migration, and invasion of A549 cells. Western blotting analyses indicated that overexpression of miR-16 down-regulated the expression of MMP-19. Additionally, the dual-luciferase reporter gene assay determined that miR-16 directly regulated the expression of MMP-16. CONCLUSIONS The present study demonstrates that miR-16 acts as a tumor-suppressor gene by inhibiting the proliferation, migration, and invasion of NSCLC cells via downregulating MMP-19 expression.
Collapse
Affiliation(s)
- G Tian
- Department of Respiratory Medicine, Affiliated Hospital of Jining Medical University, Jining, China.
| | | | | | | | | | | |
Collapse
|
42
|
Aartsen M, Abbasi R, Ackermann M, Adams J, Aguilar J, Ahlers M, Ahrens M, Alispach C, Amin N, Andeen K, Anderson T, Ansseau I, Anton G, Argüelles C, Auffenberg J, Axani S, Bagherpour H, Bai X, Balagopal V. A, Barbano A, Barwick S, Bastian B, Basu V, Baum V, Baur S, Bay R, Beatty J, Becker KH, Becker Tjus J, BenZvi S, Berley D, Bernardini E, Besson D, Binder G, Bindig D, Blaufuss E, Blot S, Bohm C, Böser S, Botner O, Böttcher J, Bourbeau E, Bourbeau J, Bradascio F, Braun J, Bron S, Brostean-Kaiser J, Burgman A, Buscher J, Busse R, Carver T, Chen C, Cheung E, Chirkin D, Choi S, Clark B, Clark K, Classen L, Coleman A, Collin G, Conrad J, Coppin P, Correa P, Cowen D, Cross R, Dave P, De Clercq C, DeLaunay J, Dembinski H, Deoskar K, De Ridder S, Desai A, Desiati P, de Vries K, de Wasseige G, de With M, DeYoung T, Dharani S, Diaz A, Díaz-Vélez J, Dujmovic H, Dunkman M, DuVernois M, Dvorak E, Ehrhardt T, Eller P, Engel R, Evenson P, Fahey S, Fazely A, Fedynitch A, Felde J, Fienberg A, Filimonov K, Finley C, Fox D, Franckowiak A, Friedman E, Fritz A, Gaisser T, Gallagher J, Ganster E, Garrappa S, Gerhardt L, Glauch T, Glüsenkamp T, Goldschmidt A, Gonzalez J, Grant D, Grégoire T, Griffith Z, Griswold S, Günder M, Gündüz M, Haack C, Hallgren A, Halliday R, Halve L, Halzen F, Hanson K, Hardin J, Haungs A, Hauser S, Hebecker D, Heereman D, Heix P, Helbing K, Hellauer R, Henningsen F, Hickford S, Hignight J, Hill G, Hoffman K, Hoffmann R, Hoinka T, Hokanson-Fasig B, Hoshina K, Huang F, Huber M, Huber T, Hultqvist K, Hünnefeld M, Hussain R, In S, Iovine N, Ishihara A, Jansson M, Japaridze G, Jeong M, Jones B, Jonske F, Joppe R, Kang D, Kang W, Kappes A, Kappesser D, Karg T, Karl M, Karle A, Katz U, Kauer M, Kellermann M, Kelley J, Kheirandish A, Kim J, Kintscher T, Kiryluk J, Kittler T, Klein S, Koirala R, Kolanoski H, Köpke L, Kopper C, Kopper S, Koskinen D, Koundal P, Kowalski M, Krings K, Krückl G, Kulacz N, Kurahashi N, Kyriacou A, Lanfranchi J, Larson M, Lauber F, Lazar J, Leonard K, Leszczyńska A, Li Y, Liu Q, Lohfink E, Lozano Mariscal C, Lu L, Lucarelli F, Ludwig A, Lünemann J, Luszczak W, Lyu Y, Ma W, Madsen J, Maggi G, Mahn K, Makino Y, Mallik P, Mancina S, Mariş I, Maruyama R, Mase K, Maunu R, McNally F, Meagher K, Medici M, Medina A, Meier M, Meighen-Berger S, Merz J, Meures T, Micallef J, Mockler D, Momenté G, Montaruli T, Moore R, Morse R, Moulai M, Muth P, Nagai R, Naumann U, Neer G, Nguyen L, Niederhausen H, Nisa M, Nowicki S, Nygren D, Obertacke Pollmann A, Oehler M, Olivas A, O’Murchadha A, O’Sullivan E, Palczewski T, Pandya H, Pankova D, Park N, Parker G, Paudel E, Peiffer P, Pérez de los Heros C, Philippen S, Pieloth D, Pieper S, Pinat E, Pizzuto A, Plum M, Popovych Y, Porcelli A, Prado Rodriguez M, Price P, Przybylski G, Raab C, Raissi A, Rameez M, Rauch L, Rawlins K, Rea I, Rehman A, Reimann R, Relethford B, Renschler M, Renzi G, Resconi E, Rhode W, Richman M, Riedel B, Robertson S, Rongen M, Rott C, Ruhe T, Ryckbosch D, Rysewyk Cantu D, Safa I, Sanchez Herrera S, Sandrock A, Sandroos J, Santander M, Sarkar S, Sarkar S, Satalecka K, Scharf M, Schaufel M, Schieler H, Schlunder P, Schmidt T, Schneider A, Schneider J, Schröder F, Schumacher L, Sclafani S, Seckel D, Seunarine S, Shefali S, Silva M, Smithers B, Snihur R, Soedingrekso J, Soldin D, Song M, Spiczak G, Spiering C, Stachurska J, Stamatikos M, Stanev T, Stein R, Stettner J, Steuer A, Stezelberger T, Stokstad R, Stößl A, Strotjohann N, Stürwald T, Stuttard T, Sullivan G, Taboada I, Tenholt F, Ter-Antonyan S, Terliuk A, Tilav S, Tollefson K, Tomankova L, Tönnis C, Toscano S, Tosi D, Trettin A, Tselengidou M, Tung C, Turcati A, Turcotte R, Turley C, Ty B, Unger E, Unland Elorrieta M, Usner M, Vandenbroucke J, Van Driessche W, van Eijk D, van Eijndhoven N, Vannerom D, van Santen J, Verpoest S, Vraeghe M, Walck C, Wallace A, Wallraff M, Watson T, Weaver C, Weindl A, Weiss M, Weldert J, Wendt C, Werthebach J, Whelan B, Whitehorn N, Wiebe K, Wiebusch C, Williams D, Wills L, Wolf M, Wood T, Woschnagg K, Wrede G, Wulff J, Xu X, Xu Y, Yanez J, Yodh G, Yoshida S, Yuan T, Zhang Z, Zöcklein M. Searching for eV-scale sterile neutrinos with eight years of atmospheric neutrinos at the IceCube Neutrino Telescope. Int J Clin Exp Med 2020. [DOI: 10.1103/physrevd.102.052009] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
43
|
Aartsen MG, Ackermann M, Adams J, Aguilar JA, Ahlers M, Ahrens M, Alispach C, Andeen K, Anderson T, Ansseau I, Anton G, Argüelles C, Auffenberg J, Axani S, Backes P, Bagherpour H, Bai X, Balagopal V A, Barbano A, Barwick SW, Bastian B, Baum V, Baur S, Bay R, Beatty JJ, Becker KH, Becker Tjus J, BenZvi S, Berley D, Bernardini E, Besson DZ, Binder G, Bindig D, Blaufuss E, Blot S, Bohm C, Böser S, Botner O, Böttcher J, Bourbeau E, Bourbeau J, Bradascio F, Braun J, Bron S, Brostean-Kaiser J, Burgman A, Buscher J, Busse RS, Carver T, Chen C, Cheung E, Chirkin D, Choi S, Clark K, Classen L, Coleman A, Collin GH, Conrad JM, Coppin P, Correa P, Cowen DF, Cross R, Dave P, De Clercq C, DeLaunay JJ, Dembinski H, Deoskar K, De Ridder S, Desiati P, de Vries KD, de Wasseige G, de With M, DeYoung T, Diaz A, Díaz-Vélez JC, Dujmovic H, Dunkman M, Dvorak E, Eberhardt B, Ehrhardt T, Eller P, Engel R, Evenson PA, Fahey S, Fazely AR, Felde J, Filimonov K, Finley C, Fox D, Franckowiak A, Friedman E, Fritz A, Gaisser TK, Gallagher J, Ganster E, Garrappa S, Gerhardt L, Ghorbani K, Glauch T, Glüsenkamp T, Goldschmidt A, Gonzalez JG, Grant D, Grégoire T, Griffith Z, Griswold S, Günder M, Gündüz M, Haack C, Hallgren A, Halliday R, Halve L, Halzen F, Hanson K, Haungs A, Hebecker D, Heereman D, Heix P, Helbing K, Hellauer R, Henningsen F, Hickford S, Hignight J, Hill GC, Hoffman KD, Hoffmann R, Hoinka T, Hokanson-Fasig B, Hoshina K, Huang F, Huber M, Huber T, Hultqvist K, Hünnefeld M, Hussain R, In S, Iovine N, Ishihara A, Jansson M, Japaridze GS, Jeong M, Jero K, Jones BJP, Jonske F, Joppe R, Kang D, Kang W, Kappes A, Kappesser D, Karg T, Karl M, Karle A, Katz U, Kauer M, Kelley JL, Kheirandish A, Kim J, Kintscher T, Kiryluk J, Kittler T, Klein SR, Koirala R, Kolanoski H, Köpke L, Kopper C, Kopper S, Koskinen DJ, Kowalski M, Krings K, Krückl G, Kulacz N, Kurahashi N, Kyriacou A, Lanfranchi JL, Larson MJ, Lauber F, Lazar JP, Leonard K, Lesiak-Bzdak M, Leszczyńska A, Leuermann M, Liu QR, Lohfink E, Lozano Mariscal CJ, Lu L, Lucarelli F, Lünemann J, Luszczak W, Lyu Y, Ma WY, Madsen J, Maggi G, Mahn KBM, Makino Y, Mallik P, Mallot K, Mancina S, Mariş IC, Maruyama R, Mase K, Maunu R, McNally F, Meagher K, Medici M, Medina A, Meier M, Meighen-Berger S, Merino G, Meures T, Micallef J, Mockler D, Momenté G, Montaruli T, Moore RW, Morse R, Moulai M, Muth P, Nagai R, Naumann U, Neer G, Niederhausen H, Nisa MU, Nowicki SC, Nygren DR, Obertacke Pollmann A, Oehler M, Olivas A, O'Murchadha A, O'Sullivan E, Palczewski T, Pandya H, Pankova DV, Park N, Peiffer P, Pérez de Los Heros C, Philippen S, Pieloth D, Pieper S, Pinat E, Pizzuto A, Plum M, Porcelli A, Price PB, Przybylski GT, Raab C, Raissi A, Rameez M, Rauch L, Rawlins K, Rea IC, Rehman A, Reimann R, Relethford B, Renschler M, Renzi G, Resconi E, Rhode W, Richman M, Robertson S, Rongen M, Rott C, Ruhe T, Ryckbosch D, Rysewyk D, Safa I, Sanchez Herrera SE, Sandrock A, Sandroos J, Santander M, Sarkar S, Sarkar S, Satalecka K, Schaufel M, Schieler H, Schlunder P, Schmidt T, Schneider A, Schneider J, Schröder FG, Schumacher L, Sclafani S, Seckel D, Seunarine S, Shefali S, Silva M, Snihur R, Soedingrekso J, Soldin D, Song M, Spiczak GM, Spiering C, Stachurska J, Stamatikos M, Stanev T, Stein R, Stettner J, Steuer A, Stezelberger T, Stokstad RG, Stößl A, Strotjohann NL, Stürwald T, Stuttard T, Sullivan GW, Taboada I, Tenholt F, Ter-Antonyan S, Terliuk A, Tilav S, Tollefson K, Tomankova L, Tönnis C, Toscano S, Tosi D, Trettin A, Tselengidou M, Tung CF, Turcati A, Turcotte R, Turley CF, Ty B, Unger E, Unland Elorrieta MA, Usner M, Vandenbroucke J, Van Driessche W, van Eijk D, van Eijndhoven N, van Santen J, Verpoest S, Vraeghe M, Walck C, Wallace A, Wallraff M, Wandkowsky N, Watson TB, Weaver C, Weindl A, Weiss MJ, Weldert J, Wendt C, Werthebach J, Whelan BJ, Whitehorn N, Wiebe K, Wiebusch CH, Wille L, Williams DR, Wills L, Wolf M, Wood J, Wood TR, Woschnagg K, Wrede G, Xu DL, Xu XW, Xu Y, Yanez JP, Yodh G, Yoshida S, Yuan T, Zöcklein M. Characteristics of the Diffuse Astrophysical Electron and Tau Neutrino Flux with Six Years of IceCube High Energy Cascade Data. Phys Rev Lett 2020; 125:121104. [PMID: 33016752 DOI: 10.1103/physrevlett.125.121104] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/26/2020] [Revised: 06/02/2020] [Accepted: 07/20/2020] [Indexed: 06/11/2023]
Abstract
We report on the first measurement of the astrophysical neutrino flux using particle showers (cascades) in IceCube data from 2010-2015. Assuming standard oscillations, the astrophysical neutrinos in this dedicated cascade sample are dominated (∼90%) by electron and tau flavors. The flux, observed in the sensitive energy range from 16 TeV to 2.6 PeV, is consistent with a single power-law model as expected from Fermi-type acceleration of high energy particles at astrophysical sources. We find the flux spectral index to be γ=2.53±0.07 and a flux normalization for each neutrino flavor of ϕ_{astro}=1.66_{-0.27}^{+0.25} at E_{0}=100 TeV, in agreement with IceCube's complementary muon neutrino results and with all-neutrino flavor fit results. In the measured energy range we reject spectral indices γ≤2.28 at ≥3σ significance level. Because of high neutrino energy resolution and low atmospheric neutrino backgrounds, this analysis provides the most detailed characterization of the neutrino flux at energies below ∼100 TeV compared to previous IceCube results. Results from fits assuming more complex neutrino flux models suggest a flux softening at high energies and a flux hardening at low energies (p value ≥0.06). The sizable and smooth flux measured below ∼100 TeV remains a puzzle. In order to not violate the isotropic diffuse gamma-ray background as measured by the Fermi Large Area Telescope, it suggests the existence of astrophysical neutrino sources characterized by dense environments which are opaque to gamma rays.
Collapse
Affiliation(s)
- M G Aartsen
- Department of Physics and Astronomy, University of Canterbury, Private Bag 4800, Christchurch, New Zealand
| | | | - J Adams
- Department of Physics and Astronomy, University of Canterbury, Private Bag 4800, Christchurch, New Zealand
| | - J A Aguilar
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - M Ahlers
- Niels Bohr Institute, University of Copenhagen, DK-2100 Copenhagen, Denmark
| | - M Ahrens
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - C Alispach
- Département de Physique Nucléaire et Corpusculaire, Université de Genève, CH-1211 Genève, Switzerland
| | - K Andeen
- Department of Physics, Marquette University, Milwaukee, Wisconsin, 53201, USA
| | - T Anderson
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - I Ansseau
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - G Anton
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - C Argüelles
- Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - J Auffenberg
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - S Axani
- Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - P Backes
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - H Bagherpour
- Department of Physics and Astronomy, University of Canterbury, Private Bag 4800, Christchurch, New Zealand
| | - X Bai
- Physics Department, South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - A Balagopal V
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - A Barbano
- Département de Physique Nucléaire et Corpusculaire, Université de Genève, CH-1211 Genève, Switzerland
| | - S W Barwick
- Department of Physics and Astronomy, University of California, Irvine, California 92697, USA
| | | | - V Baum
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - S Baur
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - R Bay
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - J J Beatty
- Department of Astronomy, Ohio State University, Columbus, Ohio 43210, USA
- Department of Physics and Center for Cosmology and Astro-Particle Physics, Ohio State University, Columbus, Ohio 43210, USA
| | - K-H Becker
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - J Becker Tjus
- Fakultät für Physik & Astronomie, Ruhr-Universität Bochum, D-44780 Bochum, Germany
| | - S BenZvi
- Department of Physics and Astronomy, University of Rochester, Rochester, New York 14627, USA
| | - D Berley
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | | | - D Z Besson
- Department of Physics and Astronomy, University of Kansas, Lawrence, Kansas 66045, USA
| | - G Binder
- Department of Physics, University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - D Bindig
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - E Blaufuss
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - S Blot
- DESY, D-15738 Zeuthen, Germany
| | - C Bohm
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - S Böser
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - O Botner
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - J Böttcher
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - E Bourbeau
- Niels Bohr Institute, University of Copenhagen, DK-2100 Copenhagen, Denmark
| | - J Bourbeau
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | | | - J Braun
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S Bron
- Département de Physique Nucléaire et Corpusculaire, Université de Genève, CH-1211 Genève, Switzerland
| | | | - A Burgman
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - J Buscher
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - R S Busse
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, D-48149 Münster, Germany
| | - T Carver
- Département de Physique Nucléaire et Corpusculaire, Université de Genève, CH-1211 Genève, Switzerland
| | - C Chen
- School of Physics and Center for Relativistic Astrophysics, Georgia Institute of Technology, Atlanta, Georgia 30332, USA
| | - E Cheung
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - D Chirkin
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S Choi
- Department of Physics, Sungkyunkwan University, Suwon 16419, Korea
| | - K Clark
- SNOLAB, 1039 Regional Road 24, Creighton Mine 9, Lively, Ontario, Canada P3Y 1N2
| | - L Classen
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, D-48149 Münster, Germany
| | - A Coleman
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - G H Collin
- Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - J M Conrad
- Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - P Coppin
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | - P Correa
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | - D F Cowen
- Department of Astronomy and Astrophysics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - R Cross
- Department of Physics and Astronomy, University of Rochester, Rochester, New York 14627, USA
| | - P Dave
- School of Physics and Center for Relativistic Astrophysics, Georgia Institute of Technology, Atlanta, Georgia 30332, USA
| | - C De Clercq
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | - J J DeLaunay
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - H Dembinski
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - K Deoskar
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - S De Ridder
- Department of Physics and Astronomy, University of Gent, B-9000 Gent, Belgium
| | - P Desiati
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - K D de Vries
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | - G de Wasseige
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | - M de With
- Institut für Physik, Humboldt-Universität zu Berlin, D-12489 Berlin, Germany
| | - T DeYoung
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - A Diaz
- Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - J C Díaz-Vélez
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - H Dujmovic
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - M Dunkman
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - E Dvorak
- Physics Department, South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - B Eberhardt
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - T Ehrhardt
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - P Eller
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - R Engel
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - P A Evenson
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - S Fahey
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - A R Fazely
- Department of Physics, Southern University, Baton Rouge, Louisiana 70813, USA
| | - J Felde
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - K Filimonov
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - C Finley
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - D Fox
- Department of Astronomy and Astrophysics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | | | - E Friedman
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - A Fritz
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - T K Gaisser
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - J Gallagher
- Department of Astronomy, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - E Ganster
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | | | - L Gerhardt
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - K Ghorbani
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - T Glauch
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - T Glüsenkamp
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - A Goldschmidt
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - J G Gonzalez
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - D Grant
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - T Grégoire
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - Z Griffith
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S Griswold
- Department of Physics and Astronomy, University of Rochester, Rochester, New York 14627, USA
| | - M Günder
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - M Gündüz
- Fakultät für Physik & Astronomie, Ruhr-Universität Bochum, D-44780 Bochum, Germany
| | - C Haack
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - A Hallgren
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - R Halliday
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - L Halve
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - F Halzen
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - K Hanson
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - A Haungs
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - D Hebecker
- Institut für Physik, Humboldt-Universität zu Berlin, D-12489 Berlin, Germany
| | - D Heereman
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - P Heix
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - K Helbing
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - R Hellauer
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - F Henningsen
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - S Hickford
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - J Hignight
- Department of Physics, University of Alberta, Edmonton, Alberta, Canada T6G 2E1
| | - G C Hill
- Department of Physics, University of Adelaide, Adelaide, 5005, Australia
| | - K D Hoffman
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - R Hoffmann
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - T Hoinka
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - B Hokanson-Fasig
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - K Hoshina
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - F Huang
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - M Huber
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - T Huber
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
- DESY, D-15738 Zeuthen, Germany
| | - K Hultqvist
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - M Hünnefeld
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - R Hussain
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S In
- Department of Physics, Sungkyunkwan University, Suwon 16419, Korea
| | - N Iovine
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - A Ishihara
- Department of Physics and Institute for Global Prominent Research, Chiba University, Chiba 263-8522, Japan
| | - M Jansson
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - G S Japaridze
- CTSPS, Clark-Atlanta University, Atlanta, Georgia 30314, USA
| | - M Jeong
- Department of Physics, Sungkyunkwan University, Suwon 16419, Korea
| | - K Jero
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - B J P Jones
- Department of Physics, University of Texas at Arlington, 502 Yates Street, Science Hall Rm 108, Box 19059, Arlington, Texas 76019, USA
| | - F Jonske
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - R Joppe
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - D Kang
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - W Kang
- Department of Physics, Sungkyunkwan University, Suwon 16419, Korea
| | - A Kappes
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, D-48149 Münster, Germany
| | - D Kappesser
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - T Karg
- DESY, D-15738 Zeuthen, Germany
| | - M Karl
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - A Karle
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - U Katz
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - M Kauer
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - J L Kelley
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - A Kheirandish
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - J Kim
- Department of Physics, Sungkyunkwan University, Suwon 16419, Korea
| | | | - J Kiryluk
- Department of Physics and Astronomy, Stony Brook University, Stony Brook, New York 11794-3800, USA
| | - T Kittler
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - S R Klein
- Department of Physics, University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - R Koirala
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - H Kolanoski
- Institut für Physik, Humboldt-Universität zu Berlin, D-12489 Berlin, Germany
| | - L Köpke
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - C Kopper
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - S Kopper
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - D J Koskinen
- Niels Bohr Institute, University of Copenhagen, DK-2100 Copenhagen, Denmark
| | - M Kowalski
- Institut für Physik, Humboldt-Universität zu Berlin, D-12489 Berlin, Germany
- DESY, D-15738 Zeuthen, Germany
| | - K Krings
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - G Krückl
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - N Kulacz
- Department of Physics, University of Alberta, Edmonton, Alberta, Canada T6G 2E1
| | - N Kurahashi
- Department of Physics, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, USA
| | - A Kyriacou
- Department of Physics, University of Adelaide, Adelaide, 5005, Australia
| | - J L Lanfranchi
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - M J Larson
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - F Lauber
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - J P Lazar
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - K Leonard
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - M Lesiak-Bzdak
- Department of Physics and Astronomy, Stony Brook University, Stony Brook, New York 11794-3800, USA
| | - A Leszczyńska
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - M Leuermann
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - Q R Liu
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - E Lohfink
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - C J Lozano Mariscal
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, D-48149 Münster, Germany
| | - L Lu
- Department of Physics and Institute for Global Prominent Research, Chiba University, Chiba 263-8522, Japan
| | - F Lucarelli
- Département de Physique Nucléaire et Corpusculaire, Université de Genève, CH-1211 Genève, Switzerland
| | - J Lünemann
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | - W Luszczak
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - Y Lyu
- Department of Physics, University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - W Y Ma
- DESY, D-15738 Zeuthen, Germany
| | - J Madsen
- Department of Physics, University of Wisconsin, River Falls, Wisconsin 54022, USA
| | - G Maggi
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | - K B M Mahn
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - Y Makino
- Department of Physics and Institute for Global Prominent Research, Chiba University, Chiba 263-8522, Japan
| | - P Mallik
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - K Mallot
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S Mancina
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - I C Mariş
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - R Maruyama
- Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - K Mase
- Department of Physics and Institute for Global Prominent Research, Chiba University, Chiba 263-8522, Japan
| | - R Maunu
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - F McNally
- Department of Physics, Mercer University, Macon, Georgia 31207-0001, USA
| | - K Meagher
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - M Medici
- Niels Bohr Institute, University of Copenhagen, DK-2100 Copenhagen, Denmark
| | - A Medina
- Department of Physics and Center for Cosmology and Astro-Particle Physics, Ohio State University, Columbus, Ohio 43210, USA
| | - M Meier
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - S Meighen-Berger
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - G Merino
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - T Meures
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - J Micallef
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - D Mockler
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - G Momenté
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - T Montaruli
- Département de Physique Nucléaire et Corpusculaire, Université de Genève, CH-1211 Genève, Switzerland
| | - R W Moore
- Department of Physics, University of Alberta, Edmonton, Alberta, Canada T6G 2E1
| | - R Morse
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - M Moulai
- Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - P Muth
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - R Nagai
- Department of Physics and Institute for Global Prominent Research, Chiba University, Chiba 263-8522, Japan
| | - U Naumann
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - G Neer
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - H Niederhausen
- Physik-department, Technische Universität München, D-85748 Garching, Germany
- Department of Physics and Astronomy, Stony Brook University, Stony Brook, New York 11794-3800, USA
| | - M U Nisa
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - S C Nowicki
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - D R Nygren
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | | | - M Oehler
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - A Olivas
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - A O'Murchadha
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - E O'Sullivan
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - T Palczewski
- Department of Physics, University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - H Pandya
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - D V Pankova
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - N Park
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - P Peiffer
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - C Pérez de Los Heros
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - S Philippen
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - D Pieloth
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - S Pieper
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - E Pinat
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - A Pizzuto
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - M Plum
- Department of Physics, Marquette University, Milwaukee, Wisconsin, 53201, USA
| | - A Porcelli
- Department of Physics and Astronomy, University of Gent, B-9000 Gent, Belgium
| | - P B Price
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - G T Przybylski
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - C Raab
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - A Raissi
- Department of Physics and Astronomy, University of Canterbury, Private Bag 4800, Christchurch, New Zealand
| | - M Rameez
- Niels Bohr Institute, University of Copenhagen, DK-2100 Copenhagen, Denmark
| | - L Rauch
- DESY, D-15738 Zeuthen, Germany
| | - K Rawlins
- Department of Physics and Astronomy, University of Alaska Anchorage, 3211 Providence Drive, Anchorage, Alaska 99508, USA
| | - I C Rea
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - A Rehman
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - R Reimann
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - B Relethford
- Department of Physics, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, USA
| | - M Renschler
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - G Renzi
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - E Resconi
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - W Rhode
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - M Richman
- Department of Physics, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, USA
| | - S Robertson
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - M Rongen
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - C Rott
- Department of Physics, Sungkyunkwan University, Suwon 16419, Korea
| | - T Ruhe
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - D Ryckbosch
- Department of Physics and Astronomy, University of Gent, B-9000 Gent, Belgium
| | - D Rysewyk
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - I Safa
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - S E Sanchez Herrera
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - A Sandrock
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - J Sandroos
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - M Santander
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - S Sarkar
- Department of Physics, University of Oxford, Parks Road, Oxford OX1 3PU, United Kingdom
| | - S Sarkar
- Department of Physics, University of Alberta, Edmonton, Alberta, Canada T6G 2E1
| | | | - M Schaufel
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - H Schieler
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - P Schlunder
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - T Schmidt
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - A Schneider
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - J Schneider
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - F G Schröder
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - L Schumacher
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - S Sclafani
- Department of Physics, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, USA
| | - D Seckel
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - S Seunarine
- Department of Physics, University of Wisconsin, River Falls, Wisconsin 54022, USA
| | - S Shefali
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - M Silva
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - R Snihur
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - J Soedingrekso
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - D Soldin
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - M Song
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - G M Spiczak
- Department of Physics, University of Wisconsin, River Falls, Wisconsin 54022, USA
| | | | | | - M Stamatikos
- Department of Physics and Center for Cosmology and Astro-Particle Physics, Ohio State University, Columbus, Ohio 43210, USA
| | - T Stanev
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - R Stein
- DESY, D-15738 Zeuthen, Germany
| | - J Stettner
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - A Steuer
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - T Stezelberger
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - R G Stokstad
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A Stößl
- Department of Physics and Institute for Global Prominent Research, Chiba University, Chiba 263-8522, Japan
| | | | - T Stürwald
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - T Stuttard
- Niels Bohr Institute, University of Copenhagen, DK-2100 Copenhagen, Denmark
| | - G W Sullivan
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - I Taboada
- School of Physics and Center for Relativistic Astrophysics, Georgia Institute of Technology, Atlanta, Georgia 30332, USA
| | - F Tenholt
- Fakultät für Physik & Astronomie, Ruhr-Universität Bochum, D-44780 Bochum, Germany
| | - S Ter-Antonyan
- Department of Physics, Southern University, Baton Rouge, Louisiana 70813, USA
| | | | - S Tilav
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - K Tollefson
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - L Tomankova
- Fakultät für Physik & Astronomie, Ruhr-Universität Bochum, D-44780 Bochum, Germany
| | - C Tönnis
- Institute of Basic Science, Sungkyunkwan University, Suwon 16419, Korea
| | - S Toscano
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - D Tosi
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | | | - M Tselengidou
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - C F Tung
- School of Physics and Center for Relativistic Astrophysics, Georgia Institute of Technology, Atlanta, Georgia 30332, USA
| | - A Turcati
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - R Turcotte
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - C F Turley
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - B Ty
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - E Unger
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - M A Unland Elorrieta
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, D-48149 Münster, Germany
| | - M Usner
- DESY, D-15738 Zeuthen, Germany
| | - J Vandenbroucke
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - W Van Driessche
- Department of Physics and Astronomy, University of Gent, B-9000 Gent, Belgium
| | - D van Eijk
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - N van Eijndhoven
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | | | - S Verpoest
- Department of Physics and Astronomy, University of Gent, B-9000 Gent, Belgium
| | - M Vraeghe
- Department of Physics and Astronomy, University of Gent, B-9000 Gent, Belgium
| | - C Walck
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - A Wallace
- Department of Physics, University of Adelaide, Adelaide, 5005, Australia
| | - M Wallraff
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - N Wandkowsky
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - T B Watson
- Department of Physics, University of Texas at Arlington, 502 Yates Street, Science Hall Rm 108, Box 19059, Arlington, Texas 76019, USA
| | - C Weaver
- Department of Physics, University of Alberta, Edmonton, Alberta, Canada T6G 2E1
| | - A Weindl
- Karlsruhe Institute of Technology, Institut für Kernphysik, D-76021 Karlsruhe, Germany
| | - M J Weiss
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - J Weldert
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - C Wendt
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - J Werthebach
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - B J Whelan
- Department of Physics, University of Adelaide, Adelaide, 5005, Australia
| | - N Whitehorn
- Department of Physics and Astronomy, UCLA, Los Angeles, California 90095, USA
| | - K Wiebe
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - C H Wiebusch
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - L Wille
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - D R Williams
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - L Wills
- Department of Physics, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, USA
| | - M Wolf
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - J Wood
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - T R Wood
- Department of Physics, University of Alberta, Edmonton, Alberta, Canada T6G 2E1
| | - K Woschnagg
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - G Wrede
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - D L Xu
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - X W Xu
- Department of Physics, Southern University, Baton Rouge, Louisiana 70813, USA
| | - Y Xu
- Department of Physics and Astronomy, Stony Brook University, Stony Brook, New York 11794-3800, USA
| | - J P Yanez
- Department of Physics, University of Alberta, Edmonton, Alberta, Canada T6G 2E1
| | - G Yodh
- Department of Physics and Astronomy, University of California, Irvine, California 92697, USA
| | - S Yoshida
- Department of Physics and Institute for Global Prominent Research, Chiba University, Chiba 263-8522, Japan
| | - T Yuan
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin, Madison, Wisconsin 53706, USA
| | - M Zöcklein
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| |
Collapse
|
44
|
Wang YM, Meng Y, Shi XN, Fan SR, Song M. [Analysis of clinical efficacy, safety and prognosis of anlotinib hydrochloride in the treatment of advanced primary liver cancer]. Zhonghua Gan Zang Bing Za Zhi 2020; 28:619-624. [PMID: 32791800 DOI: 10.3760/cma.j.cn501113-20191020-00385] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To retrospectively analyze the clinical efficacy, safety and the main factors affecting the prognosis of anlotinib hydrochloride in the treatment of advanced primary liver cancer. Methods: Fifty-five cases with advanced primary liver cancer who received anlotinib hydrochloride were enrolled. The baseline data of the patients, such as prothrombin time, total bilirubin, albumin, Child-Pugh score, procalcitonin, alpha fetoprotein, extrahepatic metastasis, cirrhosis, portal hypertension, whether or not combined surgery, pathological staging, etc before treatment were recorded. Hematological and imaging results of the patients were reviewed. Adverse events that appeared in patients at any time until the end of follow-up or loss- to- follow-up or death were recorded. The survival curve was plotted by Kaplan-Meier method, and the difference of survival time between groups was examined by log-rank test. Cox regression model of single and multiple factor were used to analyze the factors affecting the prognosis. Results: As of the last follow-up, 2 patients were lost-to-follow-up, 30 died, and 23 survived. The median survival time was 6.5 months (196 days). Grade 3 or higher adverse events included hypertension (12.73%), leukopenia (3.64%), absolute neutropenia (1.82%), thrombocytopenia (9.09%), fatigue (3.64%), anemia (1.82%), and diarrhea (1.82%). Adverse events were effectively controlled. One case had fatal ruptured esophageal varices, which were not medically related. Multivariate Cox regression analysis showed that total bilirubin (HR = 0.247, P = 0.003), albumin (HR = 0.279, P = 0.003) and procalcitonin (HR = 0.105, P = 0.012) were independent factors affecting the prognosis of advanced HCC. Conclusion: Anlotinib hydrochloride therapy is safe, effective and well tolerated in patients with advanced liver cancer, and total bilirubin, albumin, and procalcitonin are independent factors that affect the prognosis of patients with advanced liver cancer.
Collapse
Affiliation(s)
- Y M Wang
- Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - Y Meng
- Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - X N Shi
- Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - S R Fan
- Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - M Song
- Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| |
Collapse
|
45
|
Reich K, Papp KA, Armstrong AW, Wasfi Y, Li S, Shen YK, Randazzo B, Song M, Kimball AB. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol 2020; 180:1039-1049. [PMID: 30485400 DOI: 10.1111/bjd.17454] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/23/2018] [Indexed: 12/17/2022]
Abstract
BACKGROUND Long-term evaluation is required to confirm the safety profile of newer biologic agents. OBJECTIVES To report on pooled safety data from the ongoing VOYAGE 1 (NCT02207231) and VOYAGE 2 (NCT02207244) trials through 100 weeks of follow-up. METHODS Patients were randomized to either guselkumab 100 mg at weeks 0 and 4 and every 8 weeks thereafter; placebo at weeks 0, 4, 12 followed by guselkumab 100 mg at weeks 16 and 20 and every 8 weeks thereafter; or adalimumab 80 mg at week 0, 40 mg at week 1, and 40 mg every 2 weeks thereafter. Patients who received adalimumab crossed over to guselkumab at week 52 (VOYAGE 1) and at/after week 28 based on clinical response (VOYAGE 2). Open-label extensions, in which all patients received guselkumab, started at week 52 (VOYAGE 1) and week 76 (VOYAGE 2). Rates of adverse events (AEs) per 100 patient-years (PYs) are presented through 100 weeks of follow-up. RESULTS Through week 52, observed rates for guselkumab- and adalimumab-treated patients, respectively, were 262·45 per 100 PYs and 328·28 per 100 PYs for AEs, 6·20 per 100 PYs and 7·77 per 100 PYs for serious AEs (SAEs), 1·22 per 100 PYs and 1·79 per 100 PYs for serious infections (SIs), 0·28 per 100 PYs and 0·40 per 100 PYs for malignancies other than nonmelanoma skin cancers (NMSCs), 0·56 per 100 PYs and 0·40 per 100 PYs for NMSCs, and 0·47 per 100 PYs and 0·40 per 100 PYs for major adverse cardiovascular events (MACEs). Rates among patients treated with guselkumab through week 52 and week 100, respectively, were 262·45 per 100 PYs and 210·41 per 100 PYs for AEs, 6·20 and 6·29 per 100 PYs, for SAEs, 1·22 per 100 PYs and 1·06 per 100 PYs for SIs, 0·28 per 100 PYs and 0·38 per 100 PYs for malignancies, 0·56 per 100 PYs and 0·39 per 100 PYs for NMSCs, and 0·47 per 100 PYs and 0·38 per 100 PYs for MACEs. Among patients treated with adalimumab, rates of AEs, SAEs, SIs, malignancies, NMSCs, and MACEs showed some variability before and after crossover to guselkumab, although no new safety signals were noted after crossover. CONCLUSIONS The safety profile for guselkumab remains favourable through 100 weeks of treatment in patients with moderate-to-severe psoriasis.
Collapse
Affiliation(s)
- K Reich
- Dermatologikum Berlin and SCIderm Research Institute, Hamburg, Germany
| | - K A Papp
- K Papp Clinical Research and Probity Research, Inc., Waterloo, Canada
| | - A W Armstrong
- University of Southern California, Los Angeles, CA, U.S.A
| | - Y Wasfi
- Janssen Research & Development, LLC, Spring House, PA, U.S.A
| | - S Li
- Janssen Research & Development, LLC, Spring House, PA, U.S.A
| | - Y K Shen
- Janssen Research & Development, LLC, Spring House, PA, U.S.A
| | - B Randazzo
- Janssen Research & Development, LLC, Spring House, PA, U.S.A
| | - M Song
- Janssen Research & Development, LLC, Spring House, PA, U.S.A
| | - A B Kimball
- Harvard Medical School and Beth Israel Deaconess Medical Center, Inc., Boston, MA, U.S.A
| |
Collapse
|
46
|
Shin SH, Lee JS, Zhang JM, Choi S, Boskovic ZV, Zhao R, Song M, Wang R, Tian J, Lee MH, Kim JH, Jeong M, Lee JH, Petukhov M, Lee SW, Kim SG, Zou L, Byun S. Synthetic lethality by targeting the RUVBL1/2-TTT complex in mTORC1-hyperactive cancer cells. Sci Adv 2020; 6:eaay9131. [PMID: 32789167 PMCID: PMC7399646 DOI: 10.1126/sciadv.aay9131] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/29/2019] [Accepted: 03/19/2020] [Indexed: 05/08/2023]
Abstract
Despite considerable efforts, mTOR inhibitors have produced limited success in the clinic. To define the vulnerabilities of mTORC1-addicted cancer cells and to find previously unknown therapeutic targets, we investigated the mechanism of piperlongumine, a small molecule identified in a chemical library screen to specifically target cancer cells with a hyperactive mTORC1 phenotype. Sensitivity to piperlongumine was dependent on its ability to suppress RUVBL1/2-TTT, a complex involved in chromatin remodeling and DNA repair. Cancer cells with high mTORC1 activity are subjected to higher levels of DNA damage stress via c-Myc and displayed an increased dependency on RUVBL1/2 for survival and counteracting genotoxic stress. Examination of clinical cancer tissues also demonstrated that high mTORC1 activity was accompanied by high RUVBL2 expression. Our findings reveal a previously unknown role for RUVBL1/2 in cell survival, where it acts as a functional chaperone to mitigate stress levels induced in the mTORC1-Myc-DNA damage axis.
Collapse
Affiliation(s)
- Seung Ho Shin
- The Hormel Institute, University of Minnesota, Austin, MN 55912, USA
- Department of Food and Nutrition, Gyeongsang National University, Jinju 52828, Republic of Korea
- Institute of Agriculture and Life Science, Gyeongsang National University, Jinju 52828, Republic of Korea
| | - Ji Su Lee
- Division of Bioengineering, Incheon National University, Incheon 22012, Republic of Korea
| | - Jia-Min Zhang
- Massachusetts General Hospital Cancer Center, Building 149 13th Street, Charlestown, MA 02129, USA
| | - Sungbin Choi
- Division of Bioengineering, Incheon National University, Incheon 22012, Republic of Korea
| | - Zarko V. Boskovic
- Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
- Department of Medicinal Chemistry, University of Kansas, Lawrence, KS 66045, USA
| | - Ran Zhao
- School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China
| | - Mengqiu Song
- School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China
| | - Rui Wang
- School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China
| | - Jie Tian
- School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China
| | - Mee-Hyun Lee
- School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China
| | - Jae Hwan Kim
- Department of Agricultural Biotechnology, Seoul National University, Seoul 08826, Korea
| | - Minju Jeong
- Department of Agricultural Biotechnology, Seoul National University, Seoul 08826, Korea
| | - Jung Hyun Lee
- Division of Dermatology, Department of Medicine, University of Washington, Seattle, WA 98109, USA
- Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
| | - Michael Petukhov
- Petersburg Nuclear Physics Institute named after B.P. Konstantinov, NRC "Kurchatov Institute", Gatchina, Russia
- Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russia
| | - Sam W. Lee
- Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
- Yale University School of Medicine, New Haven, CT 06520, USA
| | - Sang Gyun Kim
- Department of Cell Biology, Harvard Medical School, 240 Longwood Ave, Boston, MA 02115, USA
| | - Lee Zou
- Massachusetts General Hospital Cancer Center, Building 149 13th Street, Charlestown, MA 02129, USA
- Department of Pathology, Harvard Medical School, Boston, MA 02114, USA
| | - Sanguine Byun
- Division of Bioengineering, Incheon National University, Incheon 22012, Republic of Korea
- Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
- Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea
| |
Collapse
|
47
|
Wang S, Ai Z, Song M, Yan P, Li J, Wang S. The association between vitamin D receptor FokI gene polymorphism and osteoporosis in postmenopausal women: a meta-analysis. Climacteric 2020; 24:74-79. [PMID: 32551997 DOI: 10.1080/13697137.2020.1775806] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
OBJECTIVE This study aimed to quantitatively summarize the evidence for vitamin D receptor (VDR) FokI gene polymorphism and osteoporosis risk in Caucasian and Asian postmenopausal women. MATERIALS AND METHODS The PubMed, EMBASE, Weipu, CNKI, and Wanfang databases were searched for eligible studies. Case-control studies containing available genotype frequencies for F/f were chosen, and the odds ratio (OR) with 95% confidence interval (CI) was used to assess the strength of this association. RESULTS In total, 3349 osteoporosis cases and 3202 controls were identified in our meta-analysis. In the stratified analysis, a significant association was observed between VDR FokI gene polymorphism and postmenopausal osteoporosis susceptibility in Asian subjects (additive model: OR = 1.529, 95% CI 1.053-2.219, p = 0.026; dominant model: OR 2.711, 95% CI 1.693-4.342 p < 0.001; co-dominant model: ff vs. FF, OR 2.796, 95% CI 1.439-5.433 p = 0.002), and we failed to find any significant relationship in Caucasian populations. CONCLUSION The present meta-analysis suggests that the VDR FokI genotype is associated with increased risk of osteoporosis in Asian women but not in Caucasian women. To draw comprehensive and true conclusions, further prospective studies with larger numbers of participants worldwide are needed to examine associations between VDR FokI polymorphism and osteoporosis.
Collapse
Affiliation(s)
- S Wang
- Laboratory of Molecular Biology, Hangzhou Seventh People's Hospital, Hangzhou, China
| | - Z Ai
- Institute of Genetics, Zhejiang University School of Medicine, Hangzhou, China
| | - M Song
- Laboratory of Molecular Biology, Hangzhou Seventh People's Hospital, Hangzhou, China
| | - P Yan
- Laboratory of Molecular Biology, Hangzhou Seventh People's Hospital, Hangzhou, China
| | - J Li
- Laboratory of Molecular Biology, Hangzhou Seventh People's Hospital, Hangzhou, China
| | - S Wang
- Laboratory of Molecular Biology, Hangzhou Seventh People's Hospital, Hangzhou, China
| |
Collapse
|
48
|
Reich K, Dutz J, Foley P, Thaçi D, Vender R, Song M, Miller M, You Y, Li S, Shen YK, Armstrong A. AB0759 FOUR-YEAR EFFICACY AND SAFETY OF GUSELKUMAB IN PSORIASIS PATIENTS WITH AND WITHOUT PSORIATIC ARTHRITIS: A POOLED ANALYSIS FROM VOYAGE 1 AND VOYAGE 2. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Guselkumab (GUS), a fully human monoclonal antibody, selectively binds and blocks interleukin-23. VOYAGE 1 and VOYAGE 2 are two ongoing Phase 3, randomized, double-blind, placebo (PBO)/active comparator-controlled clinical trials of GUS in patients (pts) with moderate-to-severe psoriasis (PsO).Objectives:This post-hoc analysis reports pooled results through 4 years among a subgroup of moderate-to-severe PsO pts with self-reported psoriatic arthritis (PsA) at baseline.Methods:1829 pts were randomized to GUS 100 mg at Weeks (Wks) 0, 4, and 12, then every 8 wks (q8wk); PBO at Wks 0, 4, and 12, GUS at Wks 16 and 20 then q8wk; or adalimumab (ADA) 80 mg at Wk 0, 40 mg at Wk 1, then 40 mg q2wk until Wk 47 (VOYAGE 1) or Wk 23 (VOYAGE 2). In VOYAGE 1, all pts received open-label GUS 100 mg q8wk during Wks 52-204. VOYAGE 2 incorporated a randomized withdrawal study design, followed by open-label GUS during Wks 76-204. Pooled subgroup analyses using the combined GUS group were conducted based on self-reported PsA status at baseline. Efficacy based on Investigator Global Assessment (IGA) score and Psoriasis Area and Severity Index (PASI) response was assessed using prespecified treatment failure rules (nonresponder status for all time points after discontinuing due to lack of efficacy, worsening of PsO, or use of a prohibited treatment).Results:For pooled VOYAGE 1 and VOYAGE 2 pts (N=1721), combined GUS and ADA to GUS response rates at Wks 100, 156, and 204 were: PASI 90 80.6%, 80.0%, and 80.4%; PASI 100 50.1%, 49.9%, and 52.2%; IGA 0/1 83.6%, 83.3%, and 81.7%; and IGA 0 54.3%, 52.9%, and 53.9, respectively. In the pooled subgroup analysis of pts with and without PsA, response rates were similar across the Wk 100, Wk 156, and Wk 204 evaluations (Table). Rates of adverse events through Wk 204 were comparable for pts with PsA vs those without PsA at baseline.Conclusion:Among GUS-treated pts with moderate-to-severe PsO with and without self-reported PsA at baseline, stable, durable, and high levels of skin responses, as well as comparable safety outcomes, through 4 years were observed.Table.Pooled GUS Response RatesWithout PsA at BaselineWith PsA at BaselineWk 100Wk 156Wk 204Wk 100Wk 156Wk 204N=1301N=1239N=1191N=289N=276N=264PASI 901049(80.6%)1001(80.8%)964(80.9%)233(80.6%)211 (76.4%)206(78.0%)PASI 100648(49.8%)631(50.9%)635(53.3%)149(51.6%)125 (45.3%)125 (47.3%)N=1300N=1235N=1189N=288N=276N=264IGA 0/11086(83.5%)1042(84.4%)979(82.3%)241(83.7%)217 (78.6%)208(78.8%)IGA 0702(54.0%)664(53.8%)649(54.6%)160(55.6%)135 (48.9%)134(50.8%)Acknowledgments:NoneDisclosure of Interests:Kristian Reich Grant/research support from: Janssen Research & Development, LLC, Jan Dutz Grant/research support from: Janssen Research & Development, LLC, Peter Foley Grant/research support from: Janssen Research & Development, LLC, Diamant Thaçi Grant/research support from: Janssen Research & Development, LLC, Ronald Vender Grant/research support from: Janssen Research & Development, LLC, Michael Song Employee of: Janssen Research & Development, LLC, Megan Miller Employee of: Janssen Research & Development, LLC, Yin You Employee of: Janssen Research & Development, LLC, Shu Li Employee of: Janssen Research & Development, LLC, Yaung-Kaung Shen Employee of: Janssen Research & Development, LLC, April Armstrong Grant/research support from: Janssen Research & Development, LLC
Collapse
|
49
|
Yin S, Song M, Zhao R, Liu X, Kang WK, Lee JM, Kim YE, Zhang C, Shim JH, Liu K, Dong Z, Lee MH. Xanthohumol Inhibits the Growth of Keratin 18-Overexpressed Esophageal Squamous Cell Carcinoma in vitro and in vivo. Front Cell Dev Biol 2020; 8:366. [PMID: 32509787 PMCID: PMC7248302 DOI: 10.3389/fcell.2020.00366] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2020] [Accepted: 04/24/2020] [Indexed: 12/16/2022] Open
Abstract
Esophageal squamous cell carcinoma (ESCC) is a leading cause of cancer-related death worldwide. Xanthohumol is a prenylated flavonoid isolated from hops. Although xanthohumol has been reported to exert anti-obesity, hypoglycemic, anti-hyperlipidemia and anti-cancer activities, the mechanisms underlying its chemotherapeutic activity are yet to be elucidated. In the present study, we found that xanthohumol inhibited ESCC cell proliferation in vitro and in vivo by targeting keratin (KRT)-18. Xanthohumol suppressed the proliferation, foci formation, and anchorage-independent colony growth of KYSE30 cells. Using xanthohumol-sepharose conjugated bead pull-down and mass/mass analysis, we found that KRT18 is a novel target of xanthohumol in KYSE30 cells. KRT18 protein was highly expressed in patient ESCC tissues compared to adjunct tissues. Anti-proliferative activity of xanthohumol was abrogated or enhanced according to the knockdown or overexpression of KRT18 protein, respectively. Xanthohumol also induced apoptosis and cell cycle arrest at G1 phase which was associated with the modulation of expression of related makers including cyclin D1, cyclin D3, and cleaved-PARP, Bcl-2, cytochrome c and Bax. While xanthohumol attenuated KRT18 protein expression, it failed to cause any change in the KRT18 mRNA level. Furthermore, oral administration of xanthohumol decreased tumor volume and weight in patient-derived xenografts (PDXs) tumors having overexpressed KRT18. Overall these results suggest that xanthohumol acts as a KRT18 regulator to suppress the growth of ESCC.
Collapse
Affiliation(s)
- Shuying Yin
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.,China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Mengqiu Song
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.,China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Ran Zhao
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.,China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Xuejiao Liu
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.,China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
| | - Woo Kyu Kang
- Department of Neurobiology, University of Massachusetts Medical School, Worcester, MA, United States
| | - Jeong Min Lee
- Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, United States
| | - Young Eun Kim
- Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon, South Korea
| | - Chengjuan Zhang
- The Affiliated Cancer Hospital, Zhengzhou University, Zhengzhou, China
| | - Jung-Hyun Shim
- Department of Pharmacy, College of Pharmacy, Mokpo National University, Mokpo-si, South Korea
| | - Kangdong Liu
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.,China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.,College of Korean Medicine, Dongshin University, Naju, South Korea
| | - Zigang Dong
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.,China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.,Department of Neurobiology, University of Massachusetts Medical School, Worcester, MA, United States
| | - Mee-Hyun Lee
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.,China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.,College of Korean Medicine, Dongshin University, Naju, South Korea
| |
Collapse
|
50
|
Puig L, Tsai T, Bhutani T, Uy J, Ramachandran P, Song M, You Y, Gooderham M, Lebwohl M. Safety in moderate‐to‐severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti‐tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials. J Eur Acad Dermatol Venereol 2020; 34:1744-1749. [DOI: 10.1111/jdv.16460] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2019] [Accepted: 03/27/2020] [Indexed: 01/11/2023]
Affiliation(s)
- L. Puig
- Hospital de la Santa Creu i Sant Pau Barcelona Spain
| | - T.‐F. Tsai
- National Taiwan University Hospital Taipei Taiwan
| | - T. Bhutani
- University of California San Francisco Medical Center San Francisco CA USA
| | - J. Uy
- Janssen Scientific Affairs, LLC Horsham PA USA
| | | | - M. Song
- Janssen Research & Development, LLC Spring House PA USA
| | - Y. You
- Janssen Research & Development, LLC Spring House PA USA
| | - M. Gooderham
- SKiN Centre for Dermatology Peterborough ON Canada
| | - M. Lebwohl
- Icahn School of Medicine at Mount Sinai New York NY USA
| |
Collapse
|